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ABSTRACT 
Obesity and metabolic syndrome are growing health problems worldwide and they are closely linked to 
fatty acid metabolism. Elevated free fatty acid levels are observed in both disorders. Recent studies have 
shown that fatty acids or their metabolites are linked to the pathophysiology of various diseases associated 
with obesity and metabolic syndrome. In the cytosol, fatty acids are converted to acyl-CoAs. Acyl-CoAs 
are important intermediates of lipid and glucose metabolism and they have been shown to function as 
regulators of many metabolic processes, therefore their intracellular availability is tightly controlled. This 
is achieved by the presence of binding proteins e.g. fatty acid binding proteins (FABPs), acyl-CoA binding 
protein (ACBP) and sterol carrier protein-2. Of these proteins, ACBP has the highest affinity and 
specificity towards medium and long chain acyl-CoAs. ACBP is a 10 kDa protein that is ubiquitously 
expressed throughout the body and it has been shown to be able to function as an intracellular pool former 
and transporter of acyl-CoAs. In addition, various other cellular functions have been proposed for ACBP, 
including inhibition of diazepam binding to benzodiazepine receptors. Therefore, ACBP has also been 
named as diazepam binding inhibitor (DBI). Although, ACBP has been associated with several 
biochemical processes at the cellular level, its physiological significance in mammalians is less clear. In 
order to reveal the physiological effects of this interesting protein we have created a mouse and rat lines 
overexpressing the endogenous mouse ACBP gene under the gene’s own promoter region.  
Our results show that ACBP overexpressing mice display an enlargement of the lateral ventricles, 
decreased plasticity of excitatory synapses and impairment of hippocampus-dependent form of learning 
and memory. In contrast to previous results, our animals did not show any signs of anxiety or pro-conflict 
behaviour nor did the ACBP overexpression influence the kainate or pentylenetetrazole induced seizure 
activity of transgenic mice. Furthermore, it was shown that in rats ACBP increased the liver and adipose 
tissue acyl-CoA pool size. The ACBP induced elevation was dependent on the acyl-CoA form and on the 
fed-fasted state of the animals. On the contrary, high levels of ACBP did not influence serum or plasma 
levels of other lipid forms. In addition, constant overexpression affected the glucose tolerance of 
transgenic animals only if these animals were challenged with a high fat diet enriched with medium chain 
fatty acids for four weeks. To further investigate the possible mechanisms behind these physiological 
changes we studied ACBPs influence on the mRNA levels of transcription factors involved in the 
regulation of lipid metabolism and on the protein levels of AMP-activated protein kinase (AMPK). Our 
results demonstrated that ACBP influences PPAR , PPAR  and SREBP-1 expression of the transgenic 
animals in a nutrition state dependent manner and that the regulation of SREBP-1 is mediated through 
increased AMPK protein levels. Furthermore, our results indicated that the constantly elevated levels of 
ACBP does not influence food intake or the body weight of the transgenic animals. ACBP regulates the 
hypothalamic mRNA levels of two key enzymes of fatty acid metabolism: fatty acid synthase is down-
regulated and carnitine palmitoyltransferase 1 up-regulated. In the hypothalamus, inhibition of these 
enzymes is associated with reduced food intake. In addition, ACBP down-regulates the hypothalamic 
expression levels of PPAR  and SIRT-1, transcription factors regulating lipid and glucose metabolism.  
These results demonstrate that long-term overexpression ACBP has a limited effect on the phenotype of 
transgenic mice and rats, since it does change the expression pattern of particular genes involved in 
regulation of glucose and lipid metabolism. Our findings provide new information on the physiological 
role of ACBP, especially in the regulation of transcriptions factors. 
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1. INTRODUCTION 
Obesity is a major health problem worldwide. During the last years its prevalence has increased at such 
an alarming rate that has been described even as an epidemic. According to World Health Organisation 
(WHO) in year 2005, worldwide approximately 1.6 billion adults (over 15 year old) were overweight 
(body mass index (BMI) over 25) and of these 400 million were obese (BMI over 30 in Western 
population or BMI over 27 in East Asian population). An even greater concern is that worldwide at least 
20 million children under 5 years old are overweight. Traditionally obesity has been considered as a 
problem only in the Western countries, but recent development has been the dramatic increase in the 
numbers of obese people also in the low- and middle-income countries. In Finland, recent report revealed 
that approximately 57% of men and 43% of women are overweight and that about 15% of both men and 
women are obese (Helakorpi et al., 2008). Obesity has been associated with various diseases such as type 
II diabetes, heart disease, stroke, hypertension and some cancers, to mention only a few. In addition to 
obesity, these diseases can also be considered as a part of metabolic syndrome, a condition characterized 
by a group of metabolic risk factors accumulating in one person. These include abdominal obesity, high 
blood triglyceride levels, low blood HDL cholesterol levels, elevated blood pressure and insulin 
resistance or glucose intolerance. The prevalence of metabolic syndrome and obesity go hand in hand, 
although a person with metabolic syndrome is not necessarily obese. Central obesity is more important 
than BMI in the definition of metabolic syndrome (The IDF consensus worldwide definition of the 
Metabolic syndrome, 2006). 
 
Both obesity and metabolic syndrome are closely linked to fatty acid metabolism. Hence it is not 
surprising that various enzymes and other factors regulating the metabolism of fatty acids have been 
associated with the pathology of these diseases. The fact that fatty acids and their derivates have been 
shown to be involved in the regulation of cellular metabolism makes them extremely interesting in 
understanding the cellular changes in several diseases (Jump et al., 2005). In the cytosol, free fatty acids 
are converted to acyl-CoAs. Acyl-CoAs are important intermediates of lipid and glucose metabolism, but 
in addition they have been shown to function as regulators of various metabolic processes (Corkey et al., 
2000; Faergeman and Knudsen, 1997). Especially the role of fatty acids and acyl-CoAs in the regulation 
of gene expression via their influence on different transcription factors has lately been associated with 
the pathophysiology of various diseases. In the cytosol, acyl-CoAs bind to proteins e.g. fatty acid binding 
proteins (FABPs), acyl-CoA binding protein (ACBP) and sterol carrier protein-2. These proteins act as 
pool formers and transporters of intracellular fatty acids and acyl-CoAs.  The binding properties and their 
ability to influence metabolic and regulatory functions of fatty acids and acyl-CoAs are different for each 
of these proteins. The role of FABPs in the regulation of gene expression has gained much interest. Not 
only FABPs but also ACBP has been shown to modulate the regulatory functions of acyl-CoAs 
(Knudsen et al., 2000; Schroeder et al., 2008).  
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Acyl-CoA binding protein (ACBP) is a 10 kDa protein that binds acyl-CoAs with high affinity and 
specificity. It is believed to function as an intracellular acyl-CoA pool former and transporter (Knudsen 
et al., 1993). In addition, ACBP can influence the regulatory functions of acyl-CoAs. It can release acyl-
CoA induced inhibition of certain enzymes and moreover can influence acyl-CoA mediated regulation of 
gene expression via peroxisome proliferator-activated receptors (reviewed by Schroeder et al., 2008). A 
recent study has also indicated that ACBP can influence transcriptional regulation of lipid metabolism 
through hepatocyte nuclear factor-4α (HNF-4 )(Petrescu et al., 2003). In addition to its important role in 
lipid metabolism, ACBP has been shown to displace diazepam from its binding sites on the type A -
aminobutyrate receptors (GABAA) and therefore the protein has also been named as diazepam binding 
inhibitor (DBI) (Guidotti et al., 1983). Although there is extensive data on the role of ACBP in many 
different processes, the detailed physiological importance and effects of the endogenously expressed 
form of this versatile protein are still unclear. This study aimed to investigate the different physiological 
aspects of ACBP as well as the molecular mechanism behind them. 
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2. REVIEW OF THE LITERATURE 
2.1 Acyl-CoAs 
Fatty acids are normally an important source of metabolic energy, but they also act as substrates for 
membrane biogenesis and as storage forms of energy. Free fatty acids enter the cells either by diffusion 
or by protein-mediated transport and are esterificated to acyl-CoAs by Acyl-CoA synthetase (ACS). 
Acyl-CoAs are then bound and transported by intracellular proteins such as fatty acid binding proteins 
(FABPs), acyl-CoA binding protein (ACBP) or sterol carrier protein-2. Acyl-CoAs are the active forms 
of fatty acids that can further be utilized in metabolic pathways. In addition to the extracellular import of 
free fatty acids combined to esterification, acyl-CoAs can be formed in biosynthesis from citrate through 
acetyl-CoA and malonyl-CoA. The main metabolic pathways that utilize acyl-CoAs include the 
formation of energy in mitochondrial β-oxidation, back-conversion to free fatty acids and usage as 
glycerolipids like triacylglycerols and phospholipids in membrane formation. In addition, intracellular 
acyl-CoA concentrations are also regulated by the activity of acyl-CoA hydrolases found in most 
subcellular locations. The concentration of acyl-CoAs is reported to be in the range of 5-160 μM, 
depending on tissue and metabolic state (reviewed by Faergeman and Knudsen, 1997). There are several 
factors e.g. fasting, diets, diseases such as diabetes and some drugs, which have been reported to 
influence the intracellular acyl-CoA levels. There are substantial differences also in the subcellular 
concentrations. In addition to being intermediates of cellular metabolism, acyl-CoAs have been shown to 
regulate processes like lipid and energy metabolism and signal transduction. In metabolism, acyl-CoAs 
have been shown to either inhibit or to stimulate many enzymes such as acetyl-CoA carboxylase, AMP-
activated protein kinase and acyl-CoA synthetase. In signal transduction, acyl-CoAs are indicated to 
regulate membrane trafficking, ion channels and ion pumps and dependent on the subtype either 
stimulate or inhibit the function of protein kinase C (reviewed by Corkey et al., 2000; Faergeman and 
Knudsen, 1997). Recent data has also shown that acyl-CoAs are involved in the regulation of gene 
expression through transcription factors like peroxisome proliferator-activated receptors and HNF-4α 
(Faergeman and Knudsen, 1997; Schroeder et al., 2008). 
Figure 1. Acyl-CoAs: their role in cellular 
metabolism and processes that are regulated 
by acyl-CoAs. FFA = free fatty acids, TG = 
triglycerides, FAS = fatty acid synthase, 
CPT-1 = carnitine palmitoyltransferase 1. 
 
18 
2.2 ACBP 
ACBP is a 10 kDa protein that binds acyl-CoA esters (C14 to C22) with high specificity and affinity 
(Rasmussen et al., 1990; Rosendal et al., 1993). The same, identical protein was also isolated from rat 
brain by its ability to displace diazepam from its binding sites on type A γ-aminobutyrate receptors 
(GABAA receptors) and consequently named as diazepam binding inhibitor (DBI) (Guidotti et al., 1983). 
ACBP homologues have been identified from all eukaryotics studied, including animals, plants, protozoa 
and algae. Even though ACBP homologues have not been identified in most of the bacteria and archaea 
species, some pathogenic eubacterial species have genes that resemble ACBP (Burton et al., 2005).  The 
ACBP protein is highly conserved across species; the rat and mouse proteins are 98.8% identical, while 
there is 79.3% similarity between rat and human proteins. In addition, ACBP has a broad tissue 
distribution, it has been found in all mammalian tissues investigated. This suggests that ACBP is 
associated with one or more basic cellular functions. 
2.2.1 ACBP gene 
The mouse, rat and human ACBP genes consists of four exon regions and three introns (Fig. 3), but the 
size of the gene varies from 5.6 kb in humans to 8.7 kb in rats. Also the chromosomal location of 
functional ACBP gene varies from species to species. In rats, ACBP is located in chromosome 13, while 
in humans it is in chromosome 2 and in mouse in chromosome 1. The rat ACBP gene family consists of 
one expressed, functional gene and four additional processed pseudogenes of which one was shown to 
exist in two allelic forms (Mandrup et al., 1992). Although multiple transcription initiation sites were 
observed in the rat ACBP gene, there is no evidence for alternative splicing and hence only one variant 
coding for an 87 amino acid protein is expressed (Mandrup et al., 1992). Unlike rats, both humans and 
mice have multiple variants of the ACBP gene. The mouse ACBP gene can give rise to two splice 
variants that are reported to be due to alternative usage of exon 1. The two variants are 87 and 135 amino 
acid residues long and display differences in the N-terminal part of the protein (Nitz et al., 2005). In 
mouse, there are no reported pseudogenes, although there is a gene coding for endozepine-like peptide 
(ELP) that has over 50% protein similarity with ACBP. In addition, the ligand binding motifs of these 
two proteins are highly conserved. The ELP gene has only one intron in the 5' untranslated region and 
hence it has been suggested that ELP gene might have evolved by retroposon-mediated gene duplication 
of the ancient ACBP gene (Valentin et al., 2000). In humans, there are three variants of the ACBP gene. 
They encode for proteins of 86, 88 or 104 amino acid residues (Kolmer et al., 1995; Nitz et al., 2005). 
The differences are in the N-terminal part of the proteins and do not interfere with the functional acyl-
CoA binding motifs. These alternative variants arise from differential usage of exon 1, pointing to the 
possibility of differential promoter usage.  
 
The promoter region of the rat ACBP gene displays all the key features of a housekeeping gene 
(Mandrup et al., 1992). Nevertheless, it has been demonstrated that ACBP expression levels vary from 
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tissue to tissue, with the highest levels being found from tissues, which have a high lipid turn-over. 
Furthermore, hormones, like insulin and androgens, fasting, feeding and state of cell differentiation can 
influence the ACBP gene expression (Bhuiyan et al., 1995; Hansen et al., 1991; Swinnen et al., 1996). 
The rat and human ACBP genes are regulated by transcription factors that are involved in lipid 
metabolism. Intron 1 of the rat ACBP gene contains a peroxisome proliferator activated receptor (PPAR) 
response element (PPRE) that is conserved also in human and mouse genes (Helledie et al., 2002a). This 
PPRE binds and is activated by both PPARα and PPARγ, but not PPARδ (Neess et al., 2006; Sandberg et 
al., 2005). PPRE in the intron 1 deviates from the classical PPAR  response element by having a 
guanine as a spacer between the two repeats instead of an adenine, this reduces the binding affinity of 
PPAR  (Helledie et al., 2002a). ACBP is a PPARα regulated gene, which displays a discrepancy in its 
response to fasting. PPARα is involved in the fasting response by up-regulating the gene expression. In 
contrast to the other PPAR  regulated genes, ACBP’s expression tends to be reduced by fasting 
(Bhuiyan et al., 1995). From rat ACBP gene, a second PPRE was located from the promoter region, but 
transient transfection studies revealed that it is not functional (Helledie et al., 2002a). In addition to 
PPARs, the involvement of CCAAT/enhancer binding protein (C/EBP) has been proposed, as there is a 
response element in the rat promoter region, but a more detailed investigation revealed that the rat ACBP 
gene is not activated by C/EBPα (Helledie et al., 2002a). Analysis of the human and rat ACBP promoter 
revealed the presence of a conserved sterol regulatory element (SRE)-like sequence and further studies 
confirmed that ACBP is activated by sterol regulatory element binding protein (SREBP) isoforms (Neess 
et al., 2006; Swinnen et al., 1998). The function of SREBP isoforms is enhanced by the auxiliary 
transcription factors SP-1 and nuclear factor-Y (NF-Y), whose binding sites are located upstream of the 
functional SRE element (Neess et al., 2006). The co-regulation with SREBP and PPARα might be a 
possible explanation for the reduction in ACBP transcription after fasting, since SREBP is known to be 
involved in the down-regulation of genes in response to fasting. 
 
The human ACBP gene has been considered as a candidate gene for several diseases and the occurrence 
and association of single nucleotide polymorphism (SNP) of the ACBP gene has been investigated. 
Multiple missense mutations in the ACBP gene have been found in patients suffering from 
schizophrenia. A total of 18 novel SNPs were found, three of which caused missense changes in 
conserved amino acids. The case-control association analyses of the three major SNPs showed no 
significant association with the disease (Niu et al., 2004). SNPs of the ACBP gene have also been 
investigated from patients with anxiety disorders. The exonic SNP rs8192506 was found to be associated 
with anxiety disorders with panic attacks. The rare allele guanine in the SNP was overrepresented in the 
control group. The resulting Val88Met change was determined to have a protective role against anxiety 
disorders with panic attacks (Thoeringer et al., 2007). In addition, a significant association with type 2 
diabetes and an SNP of the ACBP gene has been reported in two independent German study populations. 
A minor allele of SNP rs2084202 of the human ACBP gene was shown to be associated with a reduced 
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risk of the disease. Since the SNP is located in the promoter region of the ACBP slice variant 1-c, it was 
proposed that the SNP causing the adenine to guanine substitution could alter a site important for 
transcription regulation, thus affecting ACBP expression levels (Fisher et al., 2007). 
2.2.2 ACBP protein 
The ACBP gene codes for an approximately 10 kDa protein, depending on species and possible 
transcription variants. The protein is monomeric and forms a four-helix bundle structure. Either NMR or 
crystal structures have been published from bovine, Plasmodium falciparum and human ACBP 
(Andersen et al., 1991; Taskinen et al., 2007; van Aalten et al., 2001). All the known structures have the 
same four-helix bundle folding, with a topology of up-down-down-up. The helices A2 and A3 form a 
parallel helix pair with a 13 residue loop between them, also helices A1 and A3 are assembled as two 
parallel pairs (Fig. 2) The binding of acyl-CoA molecule induced only a few structural changes near to 
the binding pocket in all the structures studied (Kragelund et al., 1993; Taskinen et al., 2007; van Aalten 
et al., 2001). The acyl-CoA binding pocket can be divided into three parts, 1) the adenine ring binding 
pocket formed by Tyr 32 (human) and the acyl moiety of the acyl-CoA molecule. 2) The 3'-phosphate 
binding site formed by Tyr 29, Lys 33 and Lys 55 (human). 3) A hydrophobic groove for the acyl moiety 
binding formed by multiple amino acids (Taskinen et al., 2007). In all, 40% of the total binding affinity 
is accounted for by the interactions with the 3'-phosphate of the CoA part of the ligand (Faergeman et al., 
1996; Kragelund et al., 1999). The most recent data on the structure of human ACBP protein revealed 
that in addition to a monomeric binding of acyl-CoA, ACBP can also bind to acyl-CoAs in a dimeric 
form where one ACBP molecule will bind the adenine part of the acyl-CoA and the ω-end of the acyl 
chain will be bound by a second ACBP molecule (Taskinen et al., 2007). This model might help to 
explain the mechanism by which ACBP is able to accept and donate acyl-CoA molecules from various 
targets such as membrane structures and enzymes.  
 
In addition to the full-length ACBP protein, several processing products of the protein have been 
identified from rat brain and shown to have functional significance. These peptide fragments, which 
contain the same C-terminal structure originating from amino acids 33-50 of the native ACBP protein, 
are formed by posttranslational processing by endopeptidases and possess differential biological 
activities (Slobodyansky et al., 1989). Further studies have indicated that these peptides, commonly 
called endozepines, can also be found outside central nervous system. The most abundant and longest of 
these peptide fragments is triakontatetraneuropeptide, TTN which consists of amino acids 17-50 of 
native rat ACBP protein. In a hydrophobic environment, this peptide can adopt an α-helical structure 
unlike the other peptide fragments (Berkovich et al., 1990). A second processing product, which has 
been intensively studied, is called octadecaneuropeptide, ODN which consists of amino acids 33-50 of 
native rat ACBP protein. The least studied fragment is the eicosapentaneuropeptide, EPN which consist 
of amino acids 26-50 of the full-length ACBP protein (Ferrero et al., 1986b; Slobodyansky et al., 1989). 
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The occurrence of shorter fragments originating from these three processing products and their biological 
function has also been investigated. 
2.2.3 ACBP expression 
ACBP is ubiquitously expressed throughout the whole body, although there are significant differences in 
the expression levels from tissue to tissue. The highest levels are found from tissues with either high lipid 
metabolism or steroid synthesis. In certain tissues, ACBP expression is located in specialized cells. In the 
brain, the highest levels of either ACBP mRNA or ACBP-like immunoreactivity can be found in 
cerebellum, hypothalamus and reticular thalamic nucleus (Alho et al., 1985; Ball et al., 1989; Ferrarese et 
al., 1989). The ACBP expression is also localized in brain areas, in cerebellum the highest levels of 
ACBP are found in Bergmann glia, whereas levels are low in Purkinje and Golgi neurons. In the 
hypothalamus, the highest ACBP concentrations are found in the nerve terminals of the arcuate nucleus 
and median eminence (Alho et al., 1985; Alho et al., 1988). The ACBP protein and its prcessing 
products, ODN and TTN, have been detected in both neurons and in glial cells, although some suggest 
predominantly glial expression (Tong et al., 1991; Alho et al., 1995; Tonon et al., 1990). The amino acid 
sequence of rat ACBP does not have a apparent signal sequence for transmembrane passage (Mocchetti 
et al., 1986), nevertheless ACBP has been located in synaptic vesicles and it is released after nerve 
depolarisation in both rat brain tissue and in primary neuronal cultures (Costa and Guidotti, 1991). 
Recent data has shown that horizontal optokinetic stimulation of rabbit retina evokes an increased 
expression of ACBP from Müller cells. Furthermore, it was shown that threonine phosphorylated ACBP 
is also secreted from these cells after potassium chloride or phorbol myristic acetate stimulation. It is 
 
Figure 2. Schematic drawing of the bovine ACBP protein structure. N and C 
labels for the N-terminus and C-terminus of the polypeptide. The helices are 
labelled as A1, A2, A3 and A4. Modified from Taskinen et al. 2007.  
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likely that protein kinase C is responsible for the phosphorylation of ACBP (Qian et al., 2008). Unlike 
the situation in rats and humans, in Drosophila melanogaster ACBP is not expressed in the adult nervous 
system, only the larval and pupal brains of the species had detectable levels of ACBP (Kolmer et al., 
1994). In the periphery, the highest ACBP levels have been found from liver, kidney, adrenal gland, 
intestine and adipose tissue. In liver, ACBP levels are high throughout the tissue, while in kidneys and 
adrenal gland there are specialised cells containing higher levels of ACBP expression compared to the 
rest of the tissue. In adrenal cortex, high concentrations of ACBP-like immunoreactivity were found in 
the cells of zona glomerulosa, while the levels in the zona fasciculata and reticulata were considerably 
lower (Bovolin et al., 1990). In kidneys, ACBP expression is concentrated in the epithelial cells of the 
convoluted tubules and the ascending limb of the loop of Henle (Bovolin et al., 1990). High levels of 
ACBP were also found in the Leydig cells of testis (Schultz et al., 1992). In the muscle tissue, which has 
a relatively low expression of ACBP, it was observed that ACBP levels are different, depending on the 
muscle fiber type. The highest levels were found in slow-twitch oxidative soleus muscle and lowest from 
fast-twitch glycolytic white gastrocnemius. The ACBP expression in muscle correlated with the 
expression of carnitine palmitoyltransferase-1 (CPT-1) expression levels and it was found to be increased 
in obese Zucker rats (Franch et al., 2002). 
  
 
Figure 3. Main characterstics of the rat ACBP gene (A) and protein (B and C). The rat 
ACBP gene consists of four exons as indicated by numbered boxes (A). Gray boxes 
indicate known transcription regulation sites. The rat ACBP protein is a 87 amino acid 
peptide with three known processing products, the length and relative location in the 
native peptide being shown (B). Section C summarizes the structural and functional 
differences between the native ACBP protein and the two processing products. PPRE= 
peroxisome proliferator activated receptor (PPAR) response element, SRE= sterol 
regulatory element, NF-Y= nuclear factor-Y, TTN= triakontatetraneuropeptide, ODN= 
octadecaneuropeptide, EPN= eicosapentaneuropeptide, PBR= peripheral benzodiaze-
pine receptor. 
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Traditionally ACBP is considered as a cytosolic protein, although it has been shown to be secreted after 
nerve depolarisation in both rat brain tissue and in primary neuronal cultures (Costa and Guidotti, 1991). 
In the cytosol of mammalian cells, fluorescently labelled ACBP was shown localize mainly to 
endoplasmic reticulum (ER) and Golgi (Hansen et al., 2007). This localization was found to be ligand-
binding dependent; a mutated ACBP unable to bind acyl-CoAs did not shown a similar localization as 
the normal protein. Furthermore, depletion of fatty acids from cells significantly reduced the ACBP 
localization to Golgi while fatty acid overloading enhanced the association (Hansen et al., 2007). In 
addition to cytosolic localization, it has been shown that ACBP as well as its ligands, the acyl-CoAs, are 
present in the nucleus of rat liver and hepatoma cells (Elholm et al., 2000). Further experiments 
confirmed nuclear localization of ACBP also in 3T3L1 adipocytes and showed that the expression of 
ACBP in CV-1 cells resulted in substantial accumulation in nucleus (Helledie et al., 2000). 
2.2.4 Functions of ACBP 
Originally ACBP was identified as a putative modulator of type A -aminobutyrate (GABAA) receptors 
by Guidotti et al. (1983). Further studies revealed that ACBP can modulate also the function of 
peripheral-type benzodiazepine receptors (Besman et al., 1989; Guidotti et al., 1983; Yanagibashi et al., 
1988) and metabotropic receptors that are positively coupled to phospholipase C via a pertussis toxin-
sensitive G protein (do Rego et al., 2007). An identical protein was independently isolated from bovine 
liver by Morgensen et al. (1987) and was shown to bind long-chain acyl-CoA esters. Over the years, 
further effects have been added to the list of putative functions, e.g. inhibition of glucose induced insulin 
release from pancreas (Chen et al., 1988), cholecystokinin (CCK) release in intestine (Herzig et al., 
1996) and calpain activation in cell death (Shulga and Pastorino, 2006). 
2.2.4.1 Functions associated with receptor binding or central nervous system 
2.2.4.1.1 Receptor binding 
Type A -aminobutyrate (GABAA) receptors are heteropentameric membrane proteins that form ligand-
gated ion channels that respond to gamma-aminobutyric acid (GABA). Binding of GABA to the synaptic 
recognition site on the receptors leads to opening of anionic channels, allowing the influx of Cl
- 
ions 
(reviewed by Bormann 1988). In addition to the recognition site for GABA, these receptors have 
multiple modulatory binding sites for benzodiazepines, barbiturates, neurosteroids and ethanol 
(Bormann, 1988). The vast majority of the GABAA receptors are characterized by their sensitivity to 
benzodiazepines, although this response is dependent on the subunit structure of the receptor, as this 
heteropentameric peptide can be formed from several classes of subunits (α1-6, β 1-3, γ1-3, δ, ε, π and 
ρ1-3) with different modulatory properties (reviewed by Rudolph and Mohler, 2006). Early studies 
identified at least two different allosteric modulatory sites for benzodiazepines in GABAA receptors that 
are relevant for the action of ACBP. One site binds the anxiolytic benzodiazepines (diazepam) and the 
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anxiogenic β-carboline carboxylate esters. In addition, it can bind the benzodiazepine antagonist 
flumazenil (reviewed by Costa and Guidotti, 1991). The second site can bind a convulsant 
benzodiazepine, 4'-chlorodiazepam. The function of this modulatory site is resistant to flumazenil 
inhibition (Costa and Guidotti, 1991). Originally ACBP was shown to inhibit binding of [
3
H]diazepam to 
GABAA receptors, thus it was named diazepam binding inhibitor (DBI) (Guidotti et al., 1983). In 
subsequent studies, ACBP was shown to inhibit also [
3
H]methyl-beta-carboline-3-carboxylate, 
[
3
H]flumazenil and [
3
H]PK 11195 binding to various allosteric modulatory centres of GABAA receptors 
(Barbaccia et al., 1988). ACBP did not affect the gating of the GABAA receptor in the absence of GABA, 
but was demonstrated to be a negative modulator of GABA induced Cl
-
 ion conductance in primary 
cultures of spinal cord neurons and in neurons prepared from mouse embryos. The effect of ACBP was 
shown to be dose dependent (at dosages 1 to 10 μM) and was inhibited by flumazenil (Bormann et al., 
1985; Bormann, 1988). From further pharmacological profiling with recombinant rat GABAA receptors 
expressed in kidney cells, it was concluded that ACBP could function as a partial intrinsic negative 
modulator of GABAA receptors (Costa and Guidotti, 1991).  
 
In addition to GABAA, the peripheral benzodiazepine receptor (PBR, also known as translocator protein 
and mitochondrial benzodiazepine receptor) has been found to bind benzodiazepines. PBR is wildly 
expressed throughout the body, the highest levels are found in steroid producing tissues. In the central 
nervous system, PBR expression is restricted to ependymal and glial cells. Unlike GABAA, PBRs are 
intracellular receptors located mainly at mitochondrial outer membrane. The described functions of this 
receptor include regulation of steroidogenesis and apoptosis (reviewed by Casellas et al., 2002). PBR 
transports cholesterol to the inner mitochondrial membrane and therefore has been suggested to be a rate-
limiting step in the steroid and bile acid synthesis (reviewed by Lacapere and Papadopoulos, 2003). 
Binding of the benzodiazepines to PBR was found to stimulate cholesterol transport and the formation of 
steroids, although chronic administration did not have the same effect as acute treatments (Lacapere and 
Figure 4. GABAA receptor. Besides GABA 
recognition site this Cl-ionophore has 
multiple modulatory binding sites for 
benzodiazepines, barbiturates and neuro-
steroids. 
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Papadopoulos, 2003). In addition to porphyrins, ACBP has been identified as an endogenous ligand for 
PBR. Early studies revealed that ACBP lacking two carboxyterminal amino acids (Gly-Ile) could 
stimulate steroidogenesis in bovine adrenals (Besman et al., 1989; Guidotti et al., 1983). Further studies 
have confirmed that des-(Gly-Ile)-ACBP purified from rat or bovine brain and testis stimulates the 
cholesterol transport in isolated adrenocortical and Leydig cells (reviewed by Papadopoulos and Brown, 
1995). Moreover, it was shown that both native and recombinant ACBP are able to stimulate cholesterol 
loading of Cyp11a1 (first enzyme involved in synthesis steroids) in an in vitro reconstituted enzyme 
system (Brown and Hall, 1991). In addition, high affinity PBR drug ligands are displaced by ACBP 
(Bovolin et al., 1990; Garnier et al., 1993; Papadopoulos et al., 1992) and ACBP and PBRs are able to 
form a protein complex in Leydig cells (Garnier et al., 1994). The endogenous effect of ACBP has been 
studied by using ACBP knock-down with antisense oligonucleotides. Experiments in hormone 
responsive MA-10 cells and constitutively steroid producing R2C Leydig cells indicated that suppression 
of ACBP terminated the steroid production in these cells (Boujrad et al., 1993; Garnier et al., 1994). 
 
In addition to the native ACBP protein, also its processing products ODN and TTN bind and modulate 
the function of benzodiazepine receptors. The affinities and the effects of the processing products are 
different from each other and from the native ACBP protein. Differences in the affinity and effects of 
ODN and TTN can be explained by their sequence length (34 amino acids versus 18) and by differences 
in the secondary structures. ODN is able to displace [
3
H]flumazenil from rat brain membranes, but is 
unable to effect binding of [
3
H]PK 11195. On the contrary, TTN can actively displace [
3
H]PK 11195, but 
inactive against [
3
H]flumazenil binding. TTN can also enhance the inhibitory effect of picrotoxin on 
GABA-dependent [
3
H]flunitrazepam binding in a similar manner as 4'-chlordiazepam (Slobodyansky et 
al., 1989). ODN prefers the benzodiazepine sites of GABAA receptors that bind also anxiolytic 
bendodiazepines and anxiogenic β-carboline carboxylate esters and are sensitive to flumazenil, while 
TTN prefers sites that bind the convulsant benzodiazepine, 4'-chlorodiazepam, and is insensitive to 
flumazenil (reviewed by Barbaccia et al., 1990). The two processing products prefer separate binding 
sites and have a different ability to replace drug ligands from the benzodiazepine binding sites, also 
distinct from the unprocessed, native ACBP. ODN and TTN have an effect at lower concentrations 
compared to whole ACBP (Costa and Guidotti, 1991). ACBP can also be secreted in a threonine 
phosphorylated form from retinal Müller cells. It was shown that threonine phosphorylated ODN has a 
higher affinity towards the GABAA receptor compared to unphosphorylated ODN or unphosphorylated 
ACBP (Qian et al., 2008). The affinities of the ACBP, ODN and TTN towards PBRs are also different. 
ODN shows no significant affinity towards PBRs and is not able to stimulate steroid synthesis, as does 
native ACBP. On the contrary, the affinity of TTN towards PBRs is higher than that of the unprocessed 
ACBP and it is able to stimulate the steroid synthesis in cell lines in a similar fashion as native ACBP 
(Berkovich et al., 1990; Papadopoulos et al., 1991; Papadopoulos et al., 1992). 
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2.2.4.1.2 Implications of benzodiazepine receptor binding 
GABAergic neurotransmission is one of the best known inhibitory mechanisms operating in the central 
nervous system. Enhancement of GABAergic neural inhibition and hence the activation of its receptors 
represents the basis of the therapeutic treatment of many disorders and diseases like generalized anxiety, 
panic anxiety, sleep disturbances and epilepsy. ACBP can affect the function of GABAA receptors either 
directly or via neurosteroid synthesis by regulating PBR activity in glial cells. Neurosteroids are shown 
to bind and influence the activity of GABAA receptors, although the effect is dependent on the steroid 
form (Bormann, 1988). A modified version of the Vogel punishment test, a test that measures the anti-
conflict and pro-conflict activity of drugs that act at GABAA receptors, was originally utilized to 
investigate biological actions of intracerebroventicular (i.c.v.) injection of ACBP (Ferrero et al., 1986a; 
Ferrero et al., 1986b). These studies showed that ACBP could reverse the anti-conflict effects of 
diazepam and that the pro-conflict effect of ACBP was antagonised by the pre-treatment with flumazenil. 
In addition to native ACBP, also the effect of ODN and TTN has been investigated. Both processing 
products were even more potent in producing a pro-conflict action than the unprocessed protein. In drug 
ligand displacing studies, the action of ODN was competitively prevented by flumazenil, whereas TTN 
was resistant to this drug (Slobodyansky et al., 1989). It was noted that i.c.v injections of ODN in male 
mice led to increased aggressive behaviour in a dose dependent manner. This effect was reduced by the 
benzodiazepine receptor antagonist (Kavaliers and Hirst, 1986). Furthermore, i.c.v injections of ODN to 
both mouse and rats induced anxiety (De Mateos-Verchere et al., 1998). These effects were antagonised 
by both diazepam and flumazenil, indicating that the effect of ODN was being mediated through GABAA 
receptors. Interestingly, i.c.v injections of high doses of ODN did not induce tonic and/or clonic 
convulsion in rats. In this way ODN differs from native ACBP (Ferrero et al., 1986b). Furthermore, in 
mice low doses of ODN reduced convulsions and mortality induced by pentylenetetrazole (Garcia de 
Mateos-Verchere et al., 1999). Pentylenetetrazole can block GABAA receptors chloride channels and it 
has been used to evaluate the effect of anticonvulsant drugs acting on GABAA receptors. 
 
Since ACBP is involved in anxiety and pro-conflict behaviour in animals, ACBP levels have been 
determined from patients suffering from various diseases linked to either GABAA receptor function or 
neurosteroid synthesis. The level of ACBP like immunoreactivity was increased in the cerebrospinal 
fluid (CSF) of individuals with major depression with a severe anxiety component (Barbaccia et al., 
1986; Ferrero et al., 1988; Roy et al., 1988). The role of ACBP in anxiety has been further studied in 
rodents. In a study utilizing acute noise stress in rats, it was found that both ACBP and ODN protein 
levels were increased in the hippocampus of stressed animals (Ferrarese et al., 1991). Furthermore, 
psychological stress increased cerebral ACBP mRNA expression in mice, while physical stress did not 
have the same effect (Katsura et al., 2002). ACBP levels has been measured from individuals defined as 
pathological gamblers, it was found that there were increased levels of ACBP in a subgroup of patients 
showing clear signs of depression (Roy et al., 1988). Reports on patients with multi-infarct dementia or 
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dementia with Parkinson's disease indicated that there is no change in CSF ACBP-like immunoreactivity 
(Barbaccia et al., 1986; Ferrero et al., 1988). Interestingly, a subsequent study showed that Parkinsonian 
subjects with dementia have elevated ACBP levels in CSF (Ferrarese et al., 1990). There are conflicting 
results also from patients with Alzheimer's disease. Studies by Barbaccia et al. (1986) and Ferrero et al. 
(1988) reported no significant difference in ACBP like immunoreactivity between Alzheimer patients 
and controls, while Ferrarese et al. (1990) showed increased CSF ACBP levels. Furthermore, it has been 
demonstrated that beta-amyloid peptides can stimulate the ACBP mRNA expression and ACBP related 
peptide release in cultured rat astrocytes (Tokay et al., 2005). In addition, somatostatin, a peptide which 
levels have been shown to be reduced in Alzheimer's disease (Cervia and Bagnoli, 2007), can influence 
the ACBP levels. Somatostatin can decrease the expression and release of ACBP from rat astrocytes 
(Masmoudi et al., 2005). ACBP levels have been measured also from CSF of patients with various other 
diseases. In schizophrenic patients there was no change observed in ACBP levels (Barbaccia et al., 
1986), while patients with Huntington's chorea exhibited decreased ACBP levels (Ferrarese et al., 1990). 
Patients with hepatic encephalopathy showed increased cerebrospinal fluid ACBP levels. Normalization 
of the mental status of these patients reduced the ACBP levels back to normal levels (Rothstein et al., 
1989). Significantly elevated plasma ACBP levels have been measured from adult patients with epilepsy. 
Plasma levels of pediatric epilepsy patients were also elevated, although not to the same extent as seen in 
adults (Ferrarese et al., 1998). Strikingly, when the patients were divided into subgroups, it was found 
that the highest increments of ACBP levels were found from adult patients with generalized epilepsy and 
from drug-resistant adult and pediatric patients (Ferrarese et al., 1998). Previous studies with 
intrahippocampal injection ACBP peptide fragments (amino acids 42 to 50 and 43 to 50) have provided 
further evidence for a possible role of ACBP in epilepsy. Injections of these fragments to rats evoked 
limbic seizures typical of epilepsy. These seizures could be inhibited by administration of PK 11195 
(selective antagonist of the benzodiazepine receptor subtype of GABAA receptor) (Vezzani et al., 1991). 
 
Anxiety is considered to be one of the clinical features commonly found in the withdrawal syndromes 
caused by alcohol (ethanol), nicotine and morphine. A single dose of ethanol did not affect mouse 
cerebral cortex ACBP mRNA expression or the protein content, but induction of alcohol dependence by 
inhalation of alcohol vapour for 8 days caused a significant increase in both ACBP mRNA and protein 
levels in mouse cerebral cortex (Katsura et al., 1995). Furthermore, withdrawal of ethanol from these 
animals caused a further enhancement of ACBP expression (Katsura et al., 1995; Katsura et al., 1998a). 
Similar results have been obtained also from ethanol incubations of primary cultures of cerebral cortical 
neurons (Katsura et al., 1998a). In addition, long-term administration of both morphine and nicotine 
increased ACBP levels of cerebral cortex and withdrawal further increased the expression (reviewed by 
Ohkuma et al., 2001). Further studies demonstrated that the effect of nicotine to ACBP expression was 
mediated through nicotinic acetylcholine receptors (Katsura et al., 1998b), while the effect of morphine 
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occurred through activation of mu-opioid receptors, but not by kappa- or delta-opioid receptors (Katsura 
et al., 1998b; Shibasaki et al., 2007). 
2.2.4.1.3 Other central nervous system related functions 
The lateral area of hypothalamus displays high ACBP expression levels (Alho et al., 1985). This region 
has been shown to play a major role in the control of food intake. In addition, agonists of benzodiazepine 
receptors increased the palatability and evoked hyperphagic responses (Cooper, 1989). Injection of 
ACBP into the fourth ventricle of mouse suppressed the intake of 5% sucrose, water and 0.9 mM 
quinine-HCl and inhibited the preference of the animals to drink 0.05% saccharin instead of water 
(Manabe et al., 2001). Furthermore, i.c.v injection of ODN to rodents deprived of food for 10 hours 
dose-dependently reduced food intake during the 12h follow-up period (de Mateos-Verchere et al., 
2001). In rats, continuous i.c.v. infusion of ODN for 15 days reduced the food intake during the first days 
of its administration. The appetite reducing effect of ODN was not influenced by pre-treatment with 
diazepam (de Mateos-Verchere et al., 2001). Moreover, i.c.v. administration of the ODN peptide to rats 
resulted in increased expression corticotropin-releasing hormone mRNA and decreased expression of 
neuropeptide Y, both peptides known to be involved in the regulation of food intake (Compere et al., 
2005). Since diazepam, a GABAA receptor and PBR agonist does not affect the suppression of food 
intake caused by ODN, the mechanism of its function was further investigated. Recent results indicate 
that the effect of ODN is mediated through the metabotropic receptor positively coupled to 
phospholipase C via a pertussis toxin-sensitive G protein (do Rego et al., 2007). The anorexigenic effect 
of ODN has been recently demonstrated also in goldfish (Matsuda et al., 2007). In addition to the 
receptor mediated role in the regulation of food intake, ACBP might influence appetite also through acyl-
CoAs, as these esterified fatty acids have been found to play an important role in hypothalamic control of 
food intake (reviewed by Lopez et al., 2007). 
2.2.4.2 Peripheral and acyl-CoA binding associated functions 
ACBP has been shown to have important functions outside the central nervous system that are not related 
to the receptor binding ability of this protein. Consequently, ACBP was independently characterized as 
an impurity in fatty acid binding protein preparations and was shown to induce synthesis of medium 
chain acyl-CoA esters by goat mammary gland fatty acid synthetase (Mogensen et al., 1987). Further 
analysis showed that this protein is identical to ACBP/DBI isolated from rat brain.  
2.2.4.2.1 Acyl-CoA binding 
ACBP is able to bind saturated acyl-CoA esters with a carbon chain length over 8 recidues, the acyl-
CoAs with a shorter chain length (2 to 4 carbons) did not show any significant binding (Knudsen et al., 
1989; Mikkelsen and Knudsen, 1987). The acyl-CoA binding affinity of ACBP is highest towards chain 
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lengths of 14 to 22 carbons, while ability to bind shorter and longer acyl-CoA esters is considerably 
lower. ACBP binds specifically acyl-CoAs, as it exhibited no affinity towards nonesterified fatty acids 
and only low affinity towards free CoA (Kd 2 μM). ACBP showed no binding to acylcarnitines, 
cholesterol, or to a number of nucleotides (Rosendal et al., 1993). The Kd of ACBP towards acyl-CoAs 
ranged from 0.6 to 7 nM, depending on the acyl-CoA form and the method of determination (Faergeman 
et al., 1996; Schroeder et al., 2008). More detailed studies revealed that ACBPs binding affinity is 
influenced by the degree of saturation, the relative affinities being as follows: saturated > 
monounsaturated > polyunsaturated (Frolov and Schroeder, 1998; Huang et al., 2005). Evidence on the 
physiological role of ACBPs ability to bind acyl-CoA has been obtained from yeast, rat hepatoma cell 
lines and from mouse liver. In the yeast, Saccharomyces Carlsbergensis, overexpression of yeast ACBP 
gene resulted in a significant increase of intracellular acyl-CoA pool (Knudsen et al., 1994). In a rat 
hepatoma cell line, McA-RH 777, stable integration of rat ACBP cDNA led to elevated ACBP levels and 
to increased incorporation of palmitic acid when the cells were incubated with it (Yang et al., 2001). The 
most compelling data on the physiological role of ACBP in acyl-CoA pool size regulation has thus far 
been obtained from liver of a transgenic mouse line overexpressing mouse ACBP cDNA under the 
control of phosphoglycerate kinase promoter (Huang et al., 2005). These animals display a 33% 
elevation in their liver ACBP protein level, resulting in an approximately 69% increase in liver acyl-CoA 
pool. The liver acyl-CoA pool was increased in carbon chain dependent manner; mainly the levels of 
saturated and polyunsaturated acyl-CoA were increased while there was no change in the levels of 
monounsaturated acyl-CoAs. The ACBP effected also the intracellular location of the acyl-CoAs, with 
the highest increment of acyl-CoA levels found in the liver membrane/organelle fraction (Huang et al., 
2005). 
 
In vitro investigations on the effects of ACBP on the cellular function demonstrate in part the 
mechanisms by which ACBP can influence the intracellular acyl-CoA pool size and also reveal new 
intracellular effects of the protein. The ability of ACBP to extract membrane bound acyl-CoAs 
(Rasmussen et al., 1994) can increase the soluble fraction of acyl-CoAs. By binding and extracting acyl-
CoAs from membrane-associated enzyme acyl-CoA synthetase (ACS), an enzyme that converts fatty 
acids to acyl-CoAs, it was found that ACBP could release ACS of the end-product inhibition and 
enhanced its function (Rasmussen et al., 1993). In addition, the activities of acyl-CoA carboxylase 
(ACC) and adenine nucleotide translocase (ANT), two proteins involved in lipid metabolism whose 
function is inhibited by acyl-CoA, were influenced by ACBP. It has been shown that ACBP can 
efficiently release these proteins from acyl-CoA inhibition at acyl-CoA/ACBP ratios under 0.9 
(Rasmussen et al., 1993). Furthermore, ACBP was able to protect acyl-CoA esters from hydrolysis by 
microsomal hydrolases (Rasmussen et al., 1993). This in vitro data indicate that ACBP is capable of both 
increasing acyl-CoA production and decreasing its hydrolysis and hence it can increase the overall 
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intracellular acyl-CoA pool, as was proven in two cell lines and also more recently in vivo in mouse 
liver.  
 
In addition to being able to function as a pool former of acyl-CoAs, in vitro data suggests that ACBP can 
also act as an intracellular transporter of acyl-CoAs. In addition to extracting acyl-CoAs from 
membranes, ACBP can also transport the extracted acyl-CoAs to mitochondria or ER and donate them 
for either β-oxidation or glycerolipid synthesis (Rasmussen et al., 1994). The role of ACBP in the β-
oxidation was further supported by studies showing that carnitine palmitoyltransferase 1 (CPT-1), an 
enzyme mediating the transport of acyl-CoAs to mitochondrial β-oxidation, is capable of interacting with 
the acyl-CoA/ACBP complex. The activity of CPT-1 is correlated with the concentration of ACBP 
bound acyl-CoAs, but not with levels of free acyl-CoAs (Abo-Hashema et al., 2001). Also other enzymes 
have a similar preference for the acyl-CoA/ACBP complex over free acyl-CoAs. It has been claimed that 
in isolated macrophage microsomes any elevation in the ACBP concentration can inhibit the activity of 
acyl-CoA:cholesterol acyltransferase if the acyl-CoA pool is hold constant (Kerkhoff et al., 1997). On 
the contrary, a recent study has shown that in isolated liver microsomes, ACBP's influence is dependent 
on the presence of exogenous cholesterol as is the case with the other fatty acyl-CoA binding proteins 
(fatty acid binding protein and sterol carrier protein-2) involved in the regulation of acyl-CoA:cholesterol 
acyltransferase activity. This study demonstrated that in the presence of exogenous cholesterol, ACBP is 
a strong stimulator of acyl-CoA:cholesterol acyltransferase activity, whereas in the absence of exogenous 
cholesterol, ACBP functioned as an inhibitor of this enzyme (Chao et al., 2003). Similarly to CPT-1 and 
acyl-CoA:cholesterol acyltransferase, also acyl-CoA:lysophospholipid acyltransferase from human red 
blood cells preferred the acyl-CoA/ACBP complex over free acyl-CoAs (Fyrst et al., 1995). These 
results demonstrate that ACBP is able to function as an intracellular transporter of acyl-CoAs and 
possibly it can create a pool of acyl-CoAs to be directed for specific cellular purposes. In addition, 
ACBP can influence also other regulatory functions of acyl-CoAs. Peptides with S-acylation sites have 
been demonstrated to be able to be acylated at significant rates in the presence of acyl-CoAs. Addition of 
ACBP under physiological molar ratios with respect to acyl-CoAs can inhibit this process (Leventis et 
al., 1997). It is assumed that ACBP sequesters the acyl-CoAs in a complex, which is unable to serve as 
an S-acyl donor, and as a consequence, ACBP may be able to prevent the spontaneous nonenzymatic S-
acylation caused by acyl-CoAs (Leventis et al., 1997). ACBP was also demonstrated to be able to 
enhance the acyl-CoA induced activation of Ca
2+
 release channel of skeletal muscle sarcoplasmic 
reticulum, indicating that the ACBP/acyl-CoA complex either interacted directly with components of 
terminal cisternae membranes or indirectly through intermediates able to donate acyl-CoA to binding 
sites on the membranes (Fulceri et al., 1997).  
 
Besides results emerging from ACBP overexpression experiments, data on the physiological function of 
ACBP has also been obtained from knock-out and knock-down studies in yeast, Trypanosoma brucei and 
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different mammalian cell lines. In addition, there is a mouse line with a spontaneous deletion of 400 kb 
area in chromosome 1 containing the ACBP gene (Lee et al., 2007; Ohgami et al., 2005). Disruption of 
the ACB1 gene, a gene that codes for the yeast homolog of ACBP, from Saccharomyces cerevisiae 
resulted in slight reduction of the growth rate when the yeast cells were grown on ethanol, but no effect 
was observed if they were grown on glucose (Schjerling et al., 1996). Despite of the fact that ACBP 
disruption had only a limited effect on growth rates, this altered strain could not compete with wild type 
cells when they were cultivated on the same plate. Interestingly, the knock-out of ACBP in yeast resulted 
in 1.5 to 2.5 fold increase in overall intracellular acyl-CoA levels, although the increase in the acyl-CoA 
level was caused solely by de novo synthesized stearoyl-CoA (C18:0). Further experiments revealed that 
in the absence of ACBP, yeast fatty acid synthetase tended to form mainly long chain acyl-CoAs. 
Addition of ACBP resulted in a decrease in the chain length of synthesized acyl-CoAs, suggesting that 
ACBP efficiently transported the newly synthesized acyl-CoAs for further utilization (Schjerling et al., 
1996). In a more recent study utilizing the ACB1 gene depleted S. cerevisiae strain, it was noted that the 
deletion originally caused a slower growing phenotype that adapted into a faster growing phenotype 
(Gaigg et al., 2001). Further experiments with a strain having a conditional knock-out of the ACB1 gene 
detected no change in the total acyl-CoA pool, but a significant increase in stearoyl-CoA (C18:0) 
amount, as found also in the previous study. Depletion of ACBP did not affect the general glycerolipid 
synthesis; there was no change in the phospholipid pattern, rate of synthesis or in the turnover of 
phospholipid classes. In contrast, depletion of ACBP caused a reduction in total fatty acids with a chain 
length of C26:0 and also a 50-70% reduction in the sphingolipid synthesis. As a consequence the 
mutated strain accumulated 50-60 mm vesicles and autophagocytotic-like bodies in the cytosol and 
displayed perturbed plasma membrane structures. These results suggest that ACBP is involved in yeast 
membrane assembly and organization by creating a specific pool of acyl-CoAs required in membrane 
trafficking (Gaigg et al., 2001).  
 
Several mammalian cell lines have been used to study the effects of reduced ACBP expression. 
Antisense RNA or siRNA constructs have been utilized to knock-down the ACBP protein levels in 
mouse 3T3-L1 cells and in human HeLa, HepG2 and Chang cells. The ACBP antisense RNA used in 
3T3-L1 cells caused inhibition of the adipocyte differentiation process. The treated cells showed a 
significant reduction in the lipid accumulation and the morphological differentiation level of the cells 
was accordingly reduced. The inhibition of differentiation was correlated with the expression levels of 
ACBP antisense RNA (Mandrup et al., 1998). Further investigation on the effects of ACBP knock-down 
revealed that it caused a reduction in the expression of two transcription factors involved in the terminal 
stages of adipocyte differentiation, PPARγ and C/EBPα. On the other hand levels of transcription factors 
C/EBPβ and C/EBPδ, both believed to be involved in the initiation of adipocyte differentiation, were 
slightly elevated. Although knock-down of ACBP altered the differentiation of the adipocytes, it did not 
affect the clonal expansion or the growth rate of the antisense transfected 3T3-L1 cells (Mandrup et al., 
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1998). In human HeLA, HepG2 and Chang cells, the siRNA technique was utilized to knock-down the 
ACBP protein expression. Targeted knock-down resulted in visual growth arrest and detachment of cells 
in all three cell lines. ACBP depletion in HeLA cell induced apoptosis (Faergeman and Knudsen, 2002). 
Similar results have also been obtained from T. brucei in which attempts to create a total knock-out 
ACBP were unsuccessful. A conditional knock-out of ACBP in the same species showed that after 48 h 
of ACBP depletion, the cells were unable to divide and underwent cell death over the next 4 days (Milne 
et al., 2001). In contrast to the results obtained by Faergeman and Knudsen, a more recent study by 
Shulga and Pastorino (2006) found that ACBP knock-down did not cause cell apoptosis in HeLA cells, 
rather the opposite.  In their study, ACBP was found to influence the components of calpain-induced cell 
death and that the knock-down of ACBP actually inhibited cell damage (Shulga and Pastorino, 2006). 
 
A mouse line with a 400 kb deletion in chromosome 1 (nm1054 mice) has also been utilized to 
investigate the physiological effects of ACBP in vivo. Originally this mutation nm1054 arose in the 
CBA/J mouse line but it has been subsequently transferred also to C57BL/6J and 129S6/SvEvTac lines 
(Ohgami et al., 2005). The deleted region contains multiple areas that code for functional or predicted 
genes, with ACBP being one of them. With respect to ACBP, one of the most interesting phenotypes of 
the mutated mouse line is abnormal skin and hair development. The animals have sebocyte hyperplasia 
and sparse, matted hair with a greasy appearance (Lee et al., 2007). In addition, these mice show altered 
fatty acid metabolism with changes in hair triacylglycerol levels. To study in detail which of the genes 
deleted are involved in this phenotype, Lee et al. (2007) have utilized nm1054 mice with additional 
transgenic expression of specific regions originally deleted from these mice. These studies indicated that 
transgenic expression of the region containing the ACBP gene and a novel predicted gene 
3110009E18Rik (BAB29121) could reverse the skin phenotype of the mutated nm1054 mouse back to 
normal. As the authors could detect only mRNA expression of ACBP from these transgenic nm1054 
mice, they concluded that knock-out of ACBP was most likely responsible for the deranged skin and hair 
phenotype of the mouse line (Lee et al., 2007).  
2.2.4.2.2 Regulation of transcription factors 
ACBP is located in the cytosol as well as in the nucleus of cells. Using real-time imaging and 
fluorescently labelled recombinant ACBP, it was shown that about 22% of the protein is located inside 
the nucleus (Schroeder et al., 2008). In addition, acyl-CoAs have been found to modulate regulation of 
gene expression (reviewed by Black et al., 2000; Jump et al., 2005; Schroeder et al., 2008), indicating 
that ACBP might have an additional role in these processes. Studies utilizing ACBP knock-out yeast 
strains detected changes in the gene expression (Knudsen et al., 2000; Schjerling et al., 1996). Further 
studies investigating the effects of ACBP on PPAR activation have shown that ACBP could inhibit the 
trans-activation of PPAR subtypes (Helledie et al., 2000; Helledie et al., 2002b). These experiments 
utilized a monkey kidney cell line (CV-1) transfected with a reporter construct and the vector expressing 
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one of the PPAR subtypes. Tetradecylthioacetic acid (TTA), a ligand that activates all PPAR subtypes 
and is metabolized to CoA ester, or a PPARγ specific activator BRL49653 were used as activating 
ligands. Results from these studies demonstrated that ACBP attenuated the ligand induced activation of 
all three PPAR subtypes when TTA was utilized as activating agent, whereas ACBP was unable to 
influence the function of BRL49653. Furthermore, these studies showed that the effect of ACBP seemed 
to be mediated through the ligand-binding part of PPARs. These data indicate that the effect of ACBP is 
mediated through binding of the ligand that activates PPARs, not by a direct interaction with the 
transcription factor (Helledie et al., 2000; Helledie et al., 2002b).  
 
Hepatocyte nuclear factor-4α (HNF-4α) is a transcription factor regulating genes involved in both lipid 
and glucose metabolism. It has been shown that acyl-CoAs are able to either activate or inhibit the 
function of HNF-4 , depending on the chain length and degree of saturation (Hertz et al., 1998; Petrescu 
et al., 2002). Both in vitro and in vivo experiments showed that ACBP is able to physically and 
functionally interact with HNF-4α. The first line of evidence about the ability of ACBP to influence 
HNF-4α came from the fact that ACBP and HNF-4α were co-immunoprecipitated by antibodies to either 
one of these proteins. The double immunolabeling and laser scanning confocal microscopy results 
confirmed the colocalization in the nucleus and revealed that the intermolecular distance between these 
two proteins is only 53 Å. The close distance between ACBP and HNF-4α was further confirmed by 
immunogold electron microscopy, demonstrating that this colocalization is indeed specific. ACBP 
exhibited no interactions with the other nuclear proteins studied (Petrescu et al., 2003). In addition, direct 
interaction with ACBP elicits changes in the secondary structure of HNF-4  enhancing the trans-
activation (Petrescu et al., 2003). Interestingly, the ability of ACBP to increase the activity of HNF-4  is 
dependent on the ACBP/HNF-4α ratio. When the ratio is below 0.7 there is a clear correlation in the 
ACBP amount and HNF-4  activation, but with ratios higher than 0.7 the correlation disappears. This 
might be due to competition for the ligand, namely acyl-CoAs, as both proteins can bind these 
compounds with high affinities. This protein level dependent influence might be important factor 
determining the influence of ACBP on HNF-4α activity (Petrescu et al., 2003). 
2.2.4.3 Other described functions of ACBP 
ACBP has been associated with several other functions. In the duodenum, ACBP has been shown to be 
involved in trypsin sensitive cholecystokinin (CCK) release. ACBP was isolated from porcine duodenum 
in the search for a peptide responsible of proteases sensitive CCK releasing factors. Further 
investigations demonstrated that in rats ACBP is involved in the feedback regulation of pancreatic 
secretion and the postprandial release of CCK (Li et al., 2000). By utilizing STC-1 cells, a murine tumor 
cell line known to express CCK, it was shown that ACBP could elicit Ca
2+
 oscillations via the voltage-
dependent L-type Ca
2+
 channels. This change in the intracellular Ca
2+
 content resulted in increased 
secretion of CCK from these cells (Yoshida et al., 1999).  
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ACBP can alter also the endocrine secretion of pancreas. ACBP is expressed in δ- and α-cells of islets 
and in the epithelial cells of exocrine pancreas  (Chen et al., 1988; Ostenson et al., 1991). The effect of 
ACBP on pancreatic insulin secretion has been studied in several models. Utilizing isolated rat islets and 
porcine ACBP, Ostenson et al. (1990) demonstrated that ACBP did not influence the basal insulin 
secretion at 3.3 mM glucose or arginine stimulated insulin secretion, but inhibited glucose or 3-isobutyl-
1-methylxanthine stimulated insulin release. Furthermore, the negative effect of ACBP on insulin 
secretion is specific and does not change glucose stimulated release of somatostatin or the glucagon 
release (Ostenson et al., 1990; Ostenson et al., 1991). Similar results were obtained using rat ACBP in 
isolated rat islets in either static or perifusion experiments. In addition, the processing product, ODN, had 
similar effects on insulin secretion as native peptide, whereas TTN had no effect on either glucose 
stimulated or on the basal insulin secretion (Borboni et al., 1991). Further studies with the processing 
products ODN and TTN in both isolated rat islets and hamster insulinoma (HIT-T15) cells confirmed 
previous results, showing that the effects of ODN on glucose and glibenclamide stimulated insulin 
release are most likely mediated by cytoplasmic Ca
2+
 levels (De Stefanis et al., 1995). In contrast to these 
short term experiments, cultivation of fetal rat pancreatic islets enriched in beta-cells for three days in a 
medium with different concentration of porcine ACBP exhibited no effects on islet insulin and 
polyamine levels or in the insulin secretion. This long term incubation of pancreatic cells with ACBP 
resulted only in a dose-dependent inhibition of beta-cell DNA synthesis which could be overcome by 
glucose stimulation (Sjoholm et al., 1991). Intravenous infusion of ACBP to rats caused a moderate and 
transient reduction in plasma insulin levels in glucose stimulated animals. Further investigation with peri 
fused rat islets showed that ACBP was mainly affecting the acute-phase of glucose stimulated insulin 
release (Ostenson et al., 1994). These results indicate that ACBP can function as a short term modulatory 
effector of glucose stimulated insulin release. This can be either through the abilities of ACBP or ODN 
to alter the signalling pathways that influence cytoplasmic Ca
2+
 levels or through changes in the acyl-
CoA pool.  
 
ACBP has also been shown to influence cell death through calpain activation. Calpains are proteases that 
have been claimed to have an important role in apoptosis and necrosis (review by Harwood et al., 2005). 
ACBP has been proposed to function as an m- and μ-calpain activator. Activation of both calpains 
requires Ca
2+
 ions. ACBP has been demonstrated to drastically lower the Ca
2+
 concentrations needed to 
activate m-calpain, while the effect on μ-calpain is similar but less drastic. The activating effect of ACBP 
was shown to be dependent on calcium, but not to be affected by the acyl-CoA binding state of ACBP 
(Melloni et al., 2000). Further experiments have shown that ACBP has a critical role in Bid (a 
proapoptotic protein that is activated by proteolytic activation by caspase-8 or calpains) induced 
activation of calpains (Shulga and Pastorino, 2006). In isolated mitochondria, activated Bid can increase 
the ACBP content of supernatant without altering the mRNA expression of the protein. Furthermore, 
35 
knock-out of ACBP by siRNA was shown to inhibit Bid induced cell death and that ACBP required the 
presence of PBR to be able to influence the function of Bid protein. It was proposed that Bid protein can 
mediate its calpain activating and hence apoptosis activating effects through the ACBP/PBR complex, 
enabling further activation of additional Bid proteins and other apoptosis inducing factors (Shulga and 
Pastorino, 2006). 
2.3 Transcription factors 
2.3.1 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the steroid 
hormone nuclear receptor super family, which comprises a large group of ligand dependent transcription 
factors. PPARs have been claimed to have a wide range of functions in the regulation of lipid 
metabolism, energy balance and inflammation. In addition, PPARs have been shown to be involved in 
various diseases like obesity, diabetes and atherosclerosis. Like other family members, PPARs have both 
a DNA binding domain and a ligand binding domain. The C-terminal ligand binding domain directs the 
specific binding of the ligands needed for activation of the PPARs. In addition to ligand binding, this 
domain is also required for heterodimerization with the retinoid X receptor (RXR) and for undergoing an 
interaction with other transcriptional co-factors. The central DNA binding domain facilitates the binding 
of ligand activated PPARs to specific regions called PPAR response elements (PPREs) located in the 
promoters of regulated genes. Since they are ligand dependent transcription factors, activation of PPARs 
starts with binding of a specific ligand, causing a conformation change that facilitates the formation of 
the heterodimer with RXR. This complex is then able to bind to PPREs. In the absence of ligand, PPAR-
RXR heterodimers exhibit active repression by co-repressors, histone deacetylases and chromatin-
modifying factors preventing the function of PPARs. Ligand binding also facilitates the binding and 
release of accessory factors that can have a profound effect on the functionality of the complex. The 
known co-factors of PPARs include repressors like N-CoR and SMRT and activator proteins like PPARγ 
co-activator-1 (PGC-1) and CREB (reviewed by Ahmed et al., 2007; Seedorf and Aberle, 2007; Zoete et 
al., 2007). Furthermore, the activity of PPARs is regulated by various protein kinases (reviewed by 
Burns and Vanden Heuvel, 2007). The function of factors regulating PPARs is cell and tissue specific 
and although normally the PPAR complex activates gene expression, in some circumstances the effect 
may be opposite (reviewed by Ahmed et al., 2007). The PPAR family consists of three isotypes PPARα, 
PPARγ and PPARδ, which is also named PPARβ. They all share the same basic structure and method of 
activation, but have differences in their preferred ligands, tissue distribution and in the cellular processes 
that they regulate. In addition to functional differences, these proteins are encoded by separate genes. 
 
PPARα was the first member of the PPAR transcription factor family to be characterized. Originally it 
was isolated from mice and found to interact with drugs that caused peroxisomal proliferation in liver 
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(Issemann and Green, 1990), consequently all isoforms were named as peroxisome proliferator-activated 
receptors. PPARα is expressed in liver, heart, kidney, skeletal muscle, intestine and pancreas. Lower 
levels have also been detected in many other tissues. In general, PPAR  is mainly expressed in tissues 
with high oxidative capacities. In accordance to its tissue distribution, PPARα has been associated with 
regulation of fatty acid oxidation, lipid metabolism and inflammation, thus far approximately 80-100 
genes have been identified as being regulated by PPAR  (Ahmed et al., 2007). In addition to synthetic 
drug ligands, i.e. the fibrates, PPAR  ligands include both saturated and unsaturated long chain fatty 
acids, branched chain fatty acids and eicosanoids. In addition to fatty acids, also long chain acyl-CoAs 
are able to bind PPARα with high affinities. The role of acyl-CoAs on PPARα function is controversial; 
some studies have reported an inhibitory effect on gene expression through recruitment of co-repressors 
while others have shown that acyl-CoAs have activating effects on PPARα regulated genes (Reviewed 
by Gilde and Van Bilsen, 2003; Schroeder et al., 2008). 
 
The highest levels of PPARγ isoform are found in the adipose tissues. Other sites of expression include 
skeletal muscle, liver, heart, intestine and the cells of the vascular and immune system. PPARγ ligands 
include long chain polyunsaturated fatty acids, nitrated forms of some fatty acids and some 
prostaglandins. Thiazolidinedione drugs like pioglitazone and rosiglitazone serve as synthetic ligand 
activators of PPARγ. PPAR  has an essential role in adipocyte differentiation and lipid storage. In 
addition, it is involved in the regulation of glucose homeostasis and inflammation (Reviewed by Ahmed 
et al., 2007). 
 
PPARδ, is the least extensively studied isoform of the PPAR family. Compared to the other two 
isoforms, its expression is more ubiquitous, including the adipose tissue, skeletal muscle and heart. It 
seems that especially in muscle tissue, PPARδ has an important role, as its expression is 10 to 50 times 
higher than that of the other isoforms. PPARδ has been found to alter gene expression in a rather similar 
manner as PPARα, it enhances fatty acid catabolism and energy uncoupling. The main difference 
between the two isoforms is the tissues involved, with PPARα mainly affecting liver while PPARδ 
functions in muscle. PPARδ has also been indicated to regulate membrane lipid synthesis and turnover, 
fat storage and lipid accumulation in macrophages (Reviewed by Ahmed et al., 2007; Seedorf and 
Aberle, 2007). Natural ligands of PPARδ seem to include saturated fatty acids of chain length 14 to 18 
and polyunsaturated fatty acids of chain length 16 to 20. In addition, some eicosanoids have been shown 
to be able to bind PPARδ. GW501516, derivate of phenoxyacetic acid, is a specific synthetic ligand for 
PPAR  (Seedorf and Aberle, 2007). 
2.3.2 Sterol regulatory element binding proteins 
Sterol regulatory element binding proteins (SREBPs) are a family of transcription factors regulating 
genes involved in cholesterol and lipid metabolism. They have been shown to play important roles for 
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example in adipocyte differentiation and insulin-dependent gene regulation. Separate genes code for 
SREBP-1 and SREBP-2. SREBP-1 is further divided to SREBP-1a and SREBP-1c; these originate from 
the presence of a differential transcription start sites. SREBP proteins consist of an N-terminal 
transcription factor domain that is linked by two transmembrane segments to the C-terminal regulatory 
domain. SREBPs are synthesized as large precursor proteins that are inserted into the ER. Precursors are 
transported from ER to the Golgi apparatus and activated by cleavage of the transcriptional domain, 
which then can enter the nucleus. The main control of the SREBP activity occurs in the ER where the 
protein is bound by the SREBP-cleavage-activating protein (Scap), which acts as a sterol sensor. In sterol 
depleted cells, the Scap/SREBP complex is able to interact with the COPII coat proteins, enabling 
SREBP to be incorporated into vesicles and transported to the Golgi where two proteases (site 1 (S1p) 
and site 2 (S2p) proteases) cleave the peptide and release the active domain of SREBP. The released 
transcriptional domain of SREBP is transported into nucleus as a dimer by importin β, a protein required 
for the transfer of the complex across the nuclear envelope. In the presence of sterols, Scap binds also the 
sterols and hence the complex is no longer able to interact with COPII coat proteins, but rather undergoes 
interactions with Insig-1 and Insig-2 (insulin-induced genes). The binding of the Scap/SREBP complex 
to Insig proteins retains them on the ER and prevents the activation of SREBPs (reviewed by 
Bengoechea-Alonso and Ericsson, 2007; Eberle et al., 2004; Espenshade, 2006; Shimano, 2001). The 
active fragment of SREBP forms a basic helix-loop-helix leucine zipper transcription factor that is able 
to bind to both classical E-boxes and sterol regulatory elements (SREs). Maximal activation of genes by 
SREBP requires the presence of additional DNA-binding proteins, namely NF-Y, CREBP or Sp1, 
depending on the gene. The nuclear SREBPs are targets of various posttranslational modifications that 
can affect their functions; these include phosphorylation, acetylation, sumoylation and ubiquitination. A 
number of co-factors like p300, CBP and PGC-1β have also been shown to alter the regulatory functions 
of SREBPs. SREBPs are in part also regulated at the transcriptional level, for example insulin and other 
nutritional status related factors have been shown to regulate SREBP expression in various tissues. There 
is also evidence that liver X receptor (LXR) can regulate the expression of SREBP. Variation in binding 
affinities, co-regulator usage and other modifications affect differentially the functions of the three 
SREBP forms. SREBP-2 is mainly involved in the regulation of cholesterol metabolism, whereas 
SREBP-1s are involved general energy metabolism including fatty acid and glucose/insulin metabolism. 
There are further differences between SREBP-1a and SREBP-1c, with SREBP-1a being the more potent 
regulator due to its larger transcriptional domain. Overall more than 30 genes have thus far been 
identified as SREBP target genes. There are also differences in the tissue distribution between SREBP-1c 
and SREBP-1a. SREBP-1c is expressed in most tissues with high levels in liver, adipose tissue, skeletal 
muscle and brain, whereas SREBP-1a is highly expressed in certain tissues like spleen and intestine 
(reviewed by Bengoechea-Alonso and Ericsson, 2007; Espenshade, 2006; Shimano, 2001).  
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2.4 AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is one of the main regulators of energy balance, switching cells 
from an anabolic state to a catabolic state and it can influence hypothalamic regulation of food intake. 
AMPK is a heterotrimeric protein consisting of the catalytic  subunit and the regulatory β and  
subunits. There are multiple genes coding for each subunit, two for subunits  and β and three for 
subunit , making 12 possible heterotrimeric combinations (reviewed by Hardie, 2008). The  subunit 
contains a kinase domain and a C-terminal domain that interacts with the β-subunit. The β-subunit has 
domains that interact with both - and -subunits and a carbohydrate binding domain that is believed to 
function in fuel sensing. The -subunit has multiple domains involved in the activation of the complex 
(reviewed by McGee and Hargreaves, 2008).  
 
The main activator of AMPK is 5´-AMP. AMPK is activated both by a direct allosteric effect and by 5´-
AMP promoted phosphorylation of the critical threonine 172 on the -subunit. In total, 5´-AMP is able 
to induce 1000-fold increase in the kinase activity.  In addition to 5´-AMP, upstream kinases have been 
shown to activate AMPK. The most common kinase is tumor suppressor kinase LKB1 and its two 
accessory proteins STRAD and MO25 (Woods et al., 2003). A second upstream kinase believed to be 
able to phosphorylate the critical Thr 172 is calmodulin-dependent protein kinase kinase (CaMKK)-  
and –β (Hardie, 2008). At the whole body level, certain hormones such as leptin and adiponectin have 
been found to influence the activity of AMPK in various tissues. 
 
AMPK activation promotes catabolic pathways that generate ATP and at the same time it down-regulates 
anabolic pathways that consume ATP. A key pathway involved is the glucose metabolism: AMPK is 
increasing the glucose uptake of muscle tissue both by increasing translocation of glucose transporter-4 
(Glut-4) to plasma membranes and by enhancing its gene expression. In other tissues AMPK is 
influencing the glucose uptake by increasing the activity of glucose transporter-1 (Glut-1) (Hardie, 
2008).  In addition, AMPK can also induce glycolysis and inhibit gluconeogenesis. In addition, AMPK 
Figure 5. Pathways relevant for ACBP related processes that 
are activated (→) or inhibited (─┤) by AMPK. 
39 
regulates the fatty acid metabolism through acyl-CoA carboxylase (ACC). Phosphorylation of ACC by 
AMPK has been shown to inactivate it. This results in inhibition of fatty acid synthesis and through the 
reduced malonyl-CoA levels in increased oxidation of fatty acids. Malonyl-CoA can regulate the rate-
limiting step of fatty acid oxidation by inhibiting the function of CPT-1. In addition to direct effects on 
enzymes regulating metabolism, it has been shown that AMPK is involved in transcriptional regulation 
of genes. Phosphorylation by AMPK has been found to influence the function of multiple transcription 
factors and other regulators of gene expression, including PPARs and HNF-4  (reviewed by McGee and 
Hargreaves, 2008). In addition to influencing cellular energy balance, AMPK can also alter the whole 
body energy status by influencing hypothalamic regulation of food intake (Lopez et al., 2007). The 
ability of AMPK to modify a multitude of metabolic processes in many different tissues means that it is 
one of the main regulators of energy homeostasis. 
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3. AIMS OF THE STUDY 
 
The aim of this study was investigate the physiological role of acyl-CoA binding protein (ACBP) / 
diazepam binding protein (DBI) by utilizing transgenic mouse and rat lines overexpressing mouse ACBP 
gene under the control of endogenous promoter. In order to generate the animal models, the mouse 
ACBP gene was isolated and characterized.   
 
Specific aims of this thesis were 
 
1. To investigate the long-term effects of endogenously expressed ACBP in mouse central nervous 
system, in particular the role of ACBP in the behaviour of the animals. (I) 
 
2. To investigate the effects of long-term overexpression of ACBP on physiological parameters of rats 
and the molecular mechanisms behind possible changes, with a special focus on lipid and glucose 
metabolism. (II) 
 
3. To study the influence of different dietary conditions on glucose and fat metabolism in transgenic rats 
overexpressing ACBP. (III) 
 
4. To characterize the role of ACBP on gene expression regulation in the hypothalamus. (IV) 
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4. MATERIALS AND METHODS 
4.1 Isolation of mouse ACBP/DBI gene 
Mouse DBI gene was isolated from a genomic library of mouse strain 129/SvJ (Stratagene, La Jolla, CA, 
USA) by PCR screening method using two primer pairs (Israel, 1993). The first pair amplified a 255 bp 
region of the first intron of mouse DBI gene (GenBank acc. L76367). For the second primer pair, rat DBI 
gene was compared to a mouse EST sequence database in GenBank using BLAST. One EST containing 
sequence originating from intron three of mouse DBI gene was found and primers were designed to 
amplify the region from intron three to exon four of the DBI gene. The genomic library was plated into 
96 well cell culture plate at density 1000 pfu/well. Samples were analysed by PCR and secondary 
screening was performed. After tertiary screening, phages from positive wells were plated on LB-agar 
and individual plaques were picked up for PCR analysis. Positive clones were selected and subcloned 
into Bluescript KS (Stratagene). One positive clone was sequenced on both strands by primer walking 
and transposon-mediated DNA sequencing according to the manufacturer's instructions (Template 
Generation System, Finnzymes, Finland). 
4.2 Animals 
The isolated gene (GenBank AF220221) was microinjected using standard techniques into the pronuclei 
of zygotes derived from Balb/c x DBA/2 mice or from Wistar rats. In mice studies, both female and male 
adult transgenic (tg) and syngenic (sg) mice were utilized. In rat studies, adult male tg and sg animals 
were used. The weight of the rats was measured at the age of 6 weeks and 1 year. Food intake of the 6 
week old rats was measured by weighing the food pellets once a day for a period of four days. To study 
effects of changes in the nutritional status, rats were either ad libitum fed or 16 h fasted. The effect of 
high fat diets with low energy content (energy content of 13.1-13.4 KJ/kg and 44-49% of energy from 
fat) was studied with four month old male rats (average weight 380 g) that were divided into two groups: 
I. Fed with high fat diet enriched with medium chain fatty acids (MC)  (mainly octanoic (C8) and 
decanoic acid (C10), Tables 1 and 2) for 4 weeks and fasted overnight (16 h) before sample collection. II. 
Fed with high fat diet enriched with long chain fatty acids (LC) (mainly hexadecanoic (C16) and 
octadecanoic acid (C18), Tables 1 and 2) for 4 weeks and fasted as the MC diet group. The high fat diets 
were formulated (Institute of Animal Nutrition and Physiology, Kiel University) to have low energy 
content compared to commercial high fat diets (19.8 kJ kg
-1
; Table 1) in order to investigate the effects of 
different fatty acid chain lengths without interference of high energy content. To study the involvement 
of AMPK in the regulation of the transcription factors, AMPK inhibitor ((compound C (6-[4-(2-
piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine), Sigma) at a dose of 11 mg/kg 
body weight or control injections with dimethylsulphoxide were administrated i.p. to fed tg rats. Animals  
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Table 1. Composition of high fat diets used. 
Component 
LC diet MC diet 
g/kg diet 
Fat (LC = palm oil, MC = 
synthetic triglycerides) 
128.8 145.6 
Soy bean oil 30.7 30.1 
Lecithin 25.8 25.3 
Corn starch 178.5 175.1 
Casein 155.8 152.8 
Methionine 1.8 1.8 
Gelatine 11.7 11.4 
Wheat bran 31.3 30.7 
Water 386.5 379.1 
Vitamin premix 8.0 7.8 
Mineral premix 41.1 40.3 
Energy content* 13.4 kJ kg-1 13.14 kJ kg-1 
*For comparision: High fat diet from Research Diets (New 
Brunswick, NJ, USA) D12451: 19,80 kJ/kg diet (45 kcal% from fat) 
 
 
 
 
Table 2. Fatty diet composition of MC and LC diet 
Fatty acid 
LC diet MC diet 
Content g/kg diet 
C8:0 n.n 85.5 
C10:0 n.n 31.6 
C12:0 0.4 0.5 
C14:0 1.5 n.n 
C16:0 50.8 4.9 
C16:1 n.n n.n 
C18:0 59.5 1.6 
C18:1 7.6 7.1 
C18:2 21.7 21.8 
C18:3 2.9 2.9 
Others 1.0 n.n 
n.n. = Not detectable 
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were sacrificed by decapitation, tissues were collected in either liquid nitrogen or RNAlater solution 
(Qiagen, Hilden, Germany) and stored at -70°C until further analysis unless otherwise stated. All animals 
were housed in groups of two to six (two to three for rats or three to six for mice) animals per cage under 
a controlled environment (temperature 20 ± 1°C, humidity 50-60%, lights on 07.00-19.00), unless 
otherwise stated. The experiments were approved by Institutional Animal Care Committee of the 
University of Kuopio and by the Provincial Government. Procedures were conducted in accordance with 
the guidelines set by the European Community Council Directives 86/609/EEC. 
4.3 Western blotting 
Tissues were homogenized with Ultra-Turrax (IKA, Staufen, Germany) in buffer (25mM TRIS, 0.1 mM 
EDTA, 1 mM DTT and protease and phosphate inhibitor cocktails if required (Sigma, St Luis, MO, 
USA)). Equal amounts of protein were separated in SDS-PAGE and electrophoretically transferred onto 
0.2 μm nitrocellulose or PVDF membranes. Nonspecific binding was blocked by 5% powdered milk in 
TBST (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween-20). ACBP, AMPKα and Thr 172 
phosphorylated AMPKα were detected with incubation in specific antibody (ACBP 1:1000 dilution; 
Peninsula Laboratories, Bachem, Bubendorf, Switzerland or 1:400 dilution Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, AMPK and Phospho AMPKα 1:1100 dilution, Cell Signaling Technology, 
Danvers, MA, USA) followed by HRP labelled secondary antibody (1:17 000 dilution, Zymed 
Laboratories, San Francisco, CA, USA). Antibody-antigen complexes were visualized with ECL Plus 
(GE Healthcare, Chalfont St. Giles, UK). Detection was done with either Typhoon 9400 Imager (GE 
Healthcare) or Storm 860 Imager (GE Healthcare). Band densities were analyzed with ImageQuant™ TL 
program (GE Healthcare). Equal loading of the proteins was controlled with simultaneous detection of ß-
actin or α-tubulin (Cell signaling technology, 1:1500 dilution). 
4.4 Real-Time Quantitative PCR 
Total RNA was isolated from tissues by RNeasy mini kit (Qiagen, Hilden, Germany). Genomic DNA 
was digested by Dnase I (Qiagen) and RNA was reverse transcribed to cDNA (TaqMan Reverse 
Transcription Reagents, Applied Biosystems, Foster City, CA, USA). 
 
Quantitative gene expression analysis was performed on an ABI PRISM 7700 (Applied Biosystems) 
using SYBR Green technology and 18s RNA as a control gene. PCR primers (Table 3) were designed 
with eprimer3 program or taken from the literature (Hoekstra et al., 2003; Rodgers et al., 2005; 
Schmittgen and Zakrajsek, 2000). Reactions contained 2 l sample cDNA (40-60 ng), 1* SYBR Green 
master mix (Applied Biosystems), 2-15 pmol of primers in a total volume of 30 µl. All samples were 
handled as duplicates in the following conditions: 2 min at 50ºC and 10 min at 95ºC followed by 40 
cycles of 15 s at 95ºC and 1 min at 60ºC. Each assay included a relative standard curve of three serial 
dilutions of cDNA from control sample and no template controls. 
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TABLE 3: Primers used in quantitative RT-PCR. 
 
Gene Forward Reverse 
Mouse ACBP/DBI gene CACTCAGGCAACCTACATC GAACAGCATCTCTTCATCAG 
Mouse and rat ACBP mRNA GAAGCGCCTCAAGACTCAGC TTCAGCTTGTTCCACGAGTCC 
Rat PPAR α TGAACAAAGACGGGATG TCAAACTTGGGTTCCATGAT 
Rat PPAR δ GAGGGGTGCAAGGGCTTCTT CACTTGTTGCGGTTCTTCTTCTG 
Rat PPAR γ CATGCTTGTGAAGGATGCAG TTCTGAAACCGACAGACTGACT 
Rat SREBP-1 AGCGCTACCGTTCCTCTATC GCGCAAGACAGCAGATTTAT 
Mouse and rat 18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Rat SIRT-1 CAGTGTCATGGTTCCTTTGC CACCGAGGAACTACCTGAT 
Rat PGC-1α ACTGAGCTACCCTTGGGATG TAAGGATTTCGGTGGTGACA 
Rat FAS CAGTTTCCGTGAGTCCATC TCATCAAAGGTGTGCTCATC 
Rat CPT-1c AATCCTTCACCCTCATCGTC ATCCCAACTGGAAGCACTCT 
 
4.5 Histological and morphological analysis 
Mice were perfused intracardially with 20 ml of PBS and then 3x20 ml of 4% PFA. Brains were 
immerse-fixed in 4% PFA for 4 hours and moved to PBS. Cryoprotection was carried out using 20% 
sucrose in PBS for 24 hours. Brains were frozen in liquid nitrogen-isopentanol solution for 20 minutes. 
Brain slices of 16 μm were cut using cryotome. The whole brain was cut and every third slice was taken 
for staining. 
4.5.1 Immunohistochemistry 
DBI-immunoreactive neurons were stained utilizing the biotin-avidin technique (Lewis et al., 1986). 
Briefly, the sections were treated with 1% hydrogen peroxide to remove endogenous peroxidase, and 
washed in potassium phosphate–buffered saline (KPBS), pH 7.4 before blocking in 10% normal goat 
serum (NGS) and 0.5% Triton X-100 in KPBS. Thereafter, sections were incubated for 3 days (+4°C) in 
DBI antibody (1:16 000, Paesel-Lorei, Hanau, Germany) in 1% NGS, 0.5% Triton X-100 in KPBS. The 
sections were washed with KPBS containing 2% NGS before incubation for 1h with biotinylated goat 
anti-rabbit immunoglobulin G (1:1500 Vector, Burlingame, CA, USA). After washing in KPBS with 2% 
NGS, sections were incubated in avidin-biotin solution (Vectastain Elite ABC kit (Standard), Vector) for 
45 min and washed in KPBS with 2% NGS. Incubations in the secondary antibody and in the avidin–
biotin solution were repeated. The DBI-antibody complex was visualized with 0.05% 3',3'-
diaminobenzidine (DAB; Pierce Chemical, Rockford, IL, USA), and 0.05% hydrogen peroxide in KPBS. 
Sections were mounted onto gelatin-coated slides, dried overnight at 37°C, and intensified with osmium 
tetroxide and thiocarbohydrazide. 
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4.5.2 Cellular localization of DBI 
To examine the cellular localization of DBI, double immunostaining with neuronal (neuronal nuclei, 
NeuN), astrocytic (glial fibrillary acidic protein, GFAP) was performed. In short, sections were rinsed in 
KPBS, blocked in 10% normal horse serum (NHS) and incubated for 3 days at 4°C in a primary antibody 
mix containing DBI antibody (1:1000, Peninsula Laboratories) and NeuN antibody (1:15 000, Chemicon 
International, Temecula, CA, USA) or GFAP antibody (1:2000, Roche, Mannheim, Germany). After 
washing, the sections were incubated overnight at 4ºC with the secondary antibody mix containing Cy2-
conjugated donkey anti-rabbit IgG (1:200, Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) and biotinylated horse anti-mouse IgG (1:200, BA-2000, Vector, Burlingame, CA, USA) followed 
by an incubation of Cy5-conjugated streptavidin (2 μg/ml, Jackson ImmunoResearch Laboratories). 
Sections were mounted on non-gelatinized slides with GelMount and dried overnight before analysis. 
Photographs were taken from the granule cell layer and the CA3 layer of hippocampus with Nikon 
Eclipse/Ultra WIEW (Tokyo, Japan) confocal microscope. 
4.5.3 Measurement of ventricle areas 
The ventricle areas were measured from Nissl stained slides at 48 μm intervals using Stereo Investigator 
2000 (MicroBrightField, Williston, VT, USA) program in a system comprising of Olympus BX50 
microscope linked to a personal computer. Both ventricles from each section were measured blinded 
regarding to phenotype and the means were calculated. 
4.6 High resolution magnetic resonance imaging (MRI) 
Adult mice (tg n=5 and sg n=5) were anesthetized with an i.p. injection (50 μl/10 g body weight) of a 
mixture of fentanyl-fluanisone and midazolam, and externally fixed to a custom-built animal holder for 
high resolution magnetic resonance imaging (MRI). Warm air was blown through the magnet bore 
during MRI. A s.m.i.s. console (Surrey Medical Imaging Systems, Guildford, UK) interfaced to a 9.4 T 
vertical magnet (Oxford Instruments, Oxford, UK) was used for MRI with a single loop surface coil 
(diameter 27 mm) in the transmit/receive mode. Multi-slice T2-weighted images were acquired using a 
single-echo spin-echo method (time-to-repetition 3000 ms, time-to-echo 45 ms, 4 scans/line, field of 
view 25.6x12.8 mm2 (transversal) or 25.6x25.6 mm2 (coronal), matrix size 256x64 and slice thickness 
0.75 mm). 
4.7 Behavioural testing 
Five sg and 6 tg male, 12 sg and 12 tg female mice (6 months old at the time of testing) were used for 
behavioural analysis. Behavioural test battery included the tests for exploratory activity (elevated plus 
maze, light-dark box, Y-maze, open field), nociception (hot plate), coordination (beam walking, rotarod), 
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and learning and memory (fear conditioning, water maze). All tests were performed essentially as 
described by Voikar et al. (2004). 
4.7.1 Fear conditioning (FC) 
This classical conditioning analyses two memory components – association of unconditioned stimulus 
(foot-shock, US) with a particular compartment (contextual memory) and simple association of 
conditioned stimulus (tone, CS) with shock. The experiments were carried out employing a computer-
controlled fear conditioning system (TSE, Bad Homburg, Germany). Training was performed in a clear 
acrylic cage (35 x 20 x 20 cm) within a constantly illuminated (550 lx) fear conditioning box. A 
loudspeaker provided a constant, white background noise (68 dB) for 120 seconds followed by 10 kHz 
tone (CS, 75 dB, pulsed 5 Hz) for 30 seconds. The tone was terminated by a foot shock (US, 0.7 mA, 2 
seconds, constant current) delivered through a grid floor. Two CS-US pairings were separated by a 30-
second pause.  
 
Contextual memory was tested 24 h after the training. The animals were returned to the conditioning box 
and total time of freezing (defined as an absence of any movements for more than 3 seconds) was 
measured by infrared light barriers scanned continuously with a frequency of 10 Hz. The CS was not 
used during this time. Memory for CS (tone) was tested 2 h later in a novel context. New context was a 
similarly sized acrylic box. The light intensity was reduced to 100 lx, the floor was plain (without a 
shock grid) and the background colour was black (as opposed to the white colour used in training 
context). After 120 seconds of free exploration in the novel context, the CS was applied for an additional 
120 seconds and freezing was measured as above. In addition, the activity was registered in all phases of 
training and testing. Freezing behaviour and activity were later corrected for the baseline measures 
(preconditioning for context test and new context for cue test) and expressed as a change from the 
respective baselines. 
4.7.2 Water maze (WM) 
The WM test was introduced for testing spatial learning and memory in rodents (Morris, 1981). The 
system used here consisted of a black circular swimming pool (diameter 120 cm), escape platform 
(diameter 10 cm) submerged 0.5 cm under the water surface in the centre of one of four imaginary 
quadrants and computer interfaced video tracking system (EthoVision, Noldus, The Netherlands). The 
animals were released to swim in random positions facing the wall and the time to reach the escape 
platform was measured in every trial. Two training blocks consisting of three trials each were conducted 
daily. The interval between trials was about 5 min and between training blocks about 5 h. The platform 
remained in a constant location for 3 days (6 sessions) and was thereafter moved to the opposite quadrant 
for 2 days (4 sessions). The transfer tests were conducted approximately 18 h after the 4th, 6th and 10th 
training sessions. The spatial memory was estimated by the time spent in the zone around the platform 
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(covering 6.25% of the total area of the water tank) and in the corresponding zones of the three 
remaining quadrants. In addition, the swimming distance and the thigmotaxis were measured. 
Thigmotaxis was defined as the time spent swimming within the outermost ring of the water maze (10 
cm from the wall). 
4.8 Synaptic transmission and induction of long-term potentiation (LTP) 
Tg mice (n=17) and their sg littermates (n=18), 5-8 months old, were used. Both females (n=20) and 
males (n=15) were investigated to see whether a sex difference causes changes in synaptic 
neurotransmission and/or plasticity. Mice were anesthetized with halothane and brains rapidly dissected. 
Slices were obtained from the middle third of hippocampi in both hemispheres and stored in a holding 
chamber at room temperature (~24°C). The holding chamber was continuously gassed with 95% O2-5% 
CO2. Individual hippocampal slices were transferred for recording into a submerged chamber held at 32 
± 1°C with a bathing solution containing (in mM) NaCl 124, KCl 3, KH2PO4 1.25, CaCl2 3.4, MgSO4 
1.0, NaHCO3 26, D-glucose 10 and L-ascorbate 2. Slices were bubbled with 95% O2-5% CO2 to prevent 
calcium precipitation and perfused with a rate of 2.0 ml/min.  
 
Electrophysiological recordings were made from the apical dendritic field of CA1 area in the 
hippocampal slice using a glass microelectrode filled with 2 M NaCl. A Bipolar electrode made of 
twisted tungsten wire (50 μm) for stimulation was placed in the stratum radiatum of CA1 at a lateral 
distance of minimum 200 μm from the recording electrode. The stimulation intensity was adjusted to 
obtain about 50% of the maximal excitatory postsynaptic potential (EPSP) amplitude and input was 
stimulated (0.1 ms pulse duration) every 30 seconds. If the baseline of EPSP responses did not stabilize, 
the experiment was discontinued. Paired pulse facilitation (PPF) was assessed by measuring the percent 
change of the second response relative to the first response to a pair of stimulation pulses separated by 75 
msec. After a stable baseline period (20 min), LTP was elicited in the pathway by two applications of 10 
bursts (inter-burst interval 30 s) of high frequency stimulation in a 'theta burst' pattern (TBS), i.e. 100 Hz 
trains of 4 pulses separated by 200 ms (Larson and Lynch, 1986; Pussinen and Sirvio, 1998). For 
maximal induction of LTP, the stimulation intensity was increased by setting the pulse duration to 0.3 
ms. Monosynaptic field EPSPs were band-pass filtered from 0.1Hz to 3 kHz and digitized at 10 kHz. 
Data were recorded and analyzed by a microcomputer using the pCLAMP8.0 program (Axon 
Instruments, Foster City, CA, USA). 
4.9 Seizure induction 
4.9.1 Kainic acid 
26-30 mg/kg of kainate (KA) (in 0.9% NaCl, 26 – 30 mg/kg, Opika-1™ Kainic Acid, Ocean Produce 
International, Nova Scotia, Canada) was administered intraperitoneally (i.p.) to either 5 or 8 month old tg 
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and sg mice. One observer, blind to the genotype of the animals, determined the occurrence of 
behavioural seizures in mice visually for four hours after KA injection. The time to the first behavioural 
manifestations of seizures, number and severity of behavioural seizures during the 4 h follow-up period 
were scored according to a modified Racine´s scale (Lahteinen et al., 2003; Racine, 1972) 
4.9.2 Pentylenetetrazole (PTZ) 
(Sigma). Eight sg and 8 tg male mice (5 months old, weight 27.0-38.5 g) were used for studying the 
seizure threshold with PTZ. PTZ was dissolved in 0.9% NaCl and 60 mg/kg was injected i.p. Two 
observers, blind to the genotype, monitored the animals for one hour after the injection. Time to the first 
behavioural manifestations of seizures, number and severity of the seizures during the 1 hour follow-up 
were recorded. 
4.9.3 Histological evaluation 
Mice, which had been injected with 28 mg/kg KA were perfused as described above 48 hours after 
injection. Brain sections were made in the coronal plane (30 μm, one-in-five series). The amount of 
degenerating neurons after KA injection was evaluated using Fluoro-Jade B staining. After incubation in 
decreasing alcohol concentrations, the slides were bathed in a solution containing 0.06% potassium 
permanganate for 15 min, washed and incubated in Fluoro-Jade B solution containing 0.001% Fluoro 
Jade stain in acetic acid. After washing, the slides were dried, dehydrated in an alcohol series and xylene 
and mounted with DePeX. The amount of degenerating neurons in granule, hilus, CA3a, CA3b, CA3a 
and CA1 areas were visually evaluated as triplicates and scored. Evaluation started at the section where 
the suprapyramidal and infrapyramidal blades connected for the first time and continued for the six 
following sections. 
4.10 Acyl-CoA extraction and measurement 
Acyl-CoAs were extracted and measured from 6 independent samples of visceral adipose tissue and liver 
of transgenic and syngenic rats as described by Mauriala et al. (2004). In brief, tissue samples were 
powdered under liquid nitrogen and heptadecanoyl-CoA (C17:0) was added as an internal standard. 
Powdered tissues were homogenized in 5 ml ice-cold isopropanol-K2HPO4 and acidified with glacial 
acetic acid and washed with hexane-isopropanol and hexane. The hexane phase was discarded and 
proteins in lower phase were precipitated with saturated ammonium sulphate and methanol-chloroform 
solution. After centrifugation, the protein pellet was washed, centrifuged and supernatants combined. 
After addition of water the upper aqueous phase was washed with chloroform. The extracted chloroform 
phases were combined with the lower phase, washed with water and the aqueous phases from the 
extractions were then pooled. Prior to the analysis samples were dried under nitrogen and re-dissolved in 
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5% methanol-water. Acyl-CoAs were detected using on-line HPLC-ESI-MS/MS. This method was 
validated in the range of 0.1-15.0 pmol/μl of acyl-CoAs and recovery was 60±5%. 
4.11 Triglyceride, free fatty acid and cholesterol measurement 
Serum free fatty acids were measured from fed tg and sg rats using an enzymatic colorimetric method by 
NEFA C kit (Wako, Neuss, Germany). Plasma triglycerides and cholesterol were determined with 
Ecoline S reagents (DiaSyS, Holzheim, Germany). 
4.12 Glucose tolerance test (GTT) 
A glucose dose, 1 g/kg body weight, was administered i.p. to unanaesthetized rats, blood samples were 
collected from saphenous vein at 0, 10, 20, 60 and 120 min after injection. Plasma glucose was measured 
using EPOS 5060 (Eppendorf, Hamburg, Germany) and serum insulin by rat insulin ELISA (Crystal 
Chem, Downers Grove, IL, USA). 
4.13 Statistical analysis of data 
Results of the GTT and insulin levels were analyzed with two-way repeated measurements ANOVA and 
Bonferroni post-tests. Significance of differences in mean values of synaptic responses and LTP were 
tested by analysis of variance (ANOVA, MANOVA). Otherwise differences between groups were 
assessed by Student’s t – Test or Mann-Whitney U test when appropriate. Statistical significance was 
defined as p value < 0.05. All statistical tests were done using Graph Pad Prism (Graph Pad software, 
San Diego, CA, USA) or SPSS 11.5 software.  
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5. RESULTS 
5.1 Gene 
In order to create the transgenic animal lines, mouse ACBP/DBI gene was isolated from a genomic 
library. The ACBP gene (11.1 kb) consisted of 1.8 kb promoter, 4 exon regions including the recently 
found alternative exon 1 (Nitz et al., 2005) and 1.9 kb 3 ' flanking region. The promoter region contained 
various potential binding sites for transcription factors including peroxisome proliferator activated 
receptors (PPARs) that have been previously reported to take part in the regulation of ACBP/DBI 
expression (Helledie et al., 2002b). The exon/intron structure was similar to that of the rat and human 
genes. Comparison of the exon sequences with mouse ACBP/DBI cDNA revealed no base differences in 
the protein coding region. The nucleotide sequence of the isolated mouse ACBP/DBI gene has been 
submitted to GenBank database under accession number AF220221. 
5.2 ACBP expression 
5.2.1 Mouse line 
Microinjections created two mouse lines carrying the ACBP/DBI transgene. The line designated 
UKU302F was chosen for further studies on basis of higher expression levels. Transgenic (tg) mice were 
viable and fertile. Quantitative real-time PCR from genomic DNA of the tg mice confirmed that there is 
a 30 times increase in the gene copy number and the brain ACBP/DBI mRNA levels were 6.2 times 
higher in the tg animals than in their sg littermates (Paper I, Fig.1). Western blots confirmed that the tg 
animals had 37 times more ACBP/DBI protein than the sg littermates. Tg animals had elevated mRNA 
and protein levels also in the other tissues studied. 
 
The sites of transgenic expression of ACBP in the central nervous system were studied in more detail. 
Staining with ACBP/DBI antibody showed excessive expression in the infragranular region of the 
dentate gyrus in tg animals (Paper I, Fig.2). Double staining with neuron specific NeuN and glial cell 
marker GFAP demonstrated that both in the infragranular region as well as in the CA3 field of the 
hippocampus DBI was mainly expressed in glial cells (Paper I, Fig. 3). 
5.2.2 Rat line 
The isolated endogenous mouse ACBP gene (AF220221) including the promoter region was used to 
create a rat line overexpressing ACBP. Transgenic rats overexpressing ACBP were viable and fertile. 
Quantitative real-time PCR results from liver, adipose tissue and isolated hypothalamus showed that 
ACBP mRNA was about 6-27 times higher in tg animals than in sg controls (Paper II, Fig.1 and Paper 
IV, Fig.1) Especially in adipose tissue there was a considerable increase (27 times) in ACBP mRNA 
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levels. Western blot results confirmed the elevated ACBP levels. Furthermore, quantitative real-time 
PCR results revealed that in liver of transgenic (tg) animals, fasting doubled the ACBP mRNA levels 
(Paper II, Fig.1). 
 
The effects of the high fat diets on the expression of ACBP mRNA were investigated in liver and in 
visceral adipose tissue. In liver, both sg and tg rats showed a similar trend to increased ACBP expression 
with the LC diet compared to the MC diet fed rats (Paper III, Fig.1). On the contrary, in adipose tissue, 
the MC diet-fed tg rats had significantly elevated levels of ACBP compared to the LC diet fed tg rats 
(Paper III, Fig.1). There was no difference between diets in the sg controls. 
5.3 Phenotype of the mouse line 
5.3.1 Ventricle size 
Basic histology revealed enlarged ventricles in the tg animals, therefore more detailed investigations 
were performed. Mean ventricle areas were calculated for each mouse and compared between tg and sg 
animals by planemetrical analysis. Adult tg mice exhibited a significantly larger mean ventricle area than 
sg controls. In addition, the difference in ventricle size was confirmed by MRI study showing that the 
adult tg animals had a five times larger mean ventricle area than their sg littermates (Paper I, Fig. 4). 
MRI studies with newborn mice revealed that the differences were already evident at birth and evaluation 
of the rat line (Fig. 6) confirmed that the hydrocephalus is specific effect of increased ACBP levels and 
not caused by an insertional mutagenesis. 
5.3.2 Behavioural testing 
ACBP has been indicated to induce pro-conflict behaviour and anxiety (De Mateos-Verchere et al., 1998; 
Ferrero et al., 1986a; Ferrero et al., 1986b). Evaluation of the behaviour of transgenic animals showed 
that there was no major difference between the groups in motor and exploratory activity as assessed by 
open field, elevated plus maze, light-dark and Y-maze tests. Furthermore, the pain sensitivity (hot plate) 
and coordination (rotarod, beam balancing) were not affected by the overexpression of the ACBP/DBI 
transgene. Nonetheless, in the fear conditioning experiments tg males displayed significantly reduced 
Figure 6. Hydrocephalus in rats. 
MRI pictures shown enlarged 
vesicles in tg rats. Mean ventricle 
volume in sg 15.4±5.16 mm
3
 and in 
tg 53.2±37.14 mm
3
. 
52 
freezing in conditioning context (a hippocampus-dependent form of memory) as compared with sg males 
(Paper I, Fig 5). However, there was no difference between females (effect of genotype F(1,31)=3.6, 
p=0.067; interaction of genotype and sex F(1,31)=6.8, p=0.014). The extent of freezing in response to the 
conditioned stimulus (tone; amygdala-dependent) did not differ between the sg and tg mice.  
 
All groups learned to find the hidden escape platform in the water maze experiment (Paper I, Fig.6a). 
However, in the first transfer test (after 4 learning blocks), the sg mice displayed a clear preference for 
the trained quadrant whereas the tg mice did not show any spatial selectivity (Paper I, Fig. 6b). After 
prolonged training (2 additional blocks of trials) tg mice also learned to search in the trained quadrant 
(Paper I, Fig. 6c). Both groups were able to learn to find the platform in the new (opposite) location and 
showed a preference for the new zone in the third transfer test (Paper I, Fig. 6d). All mice rapidly learned 
to swim to the platform when it was made visible, confirming that they possessed sufficient motor and 
motivational abilities to perform the swimming navigation task. 
5.3.3 Long term potentiation (LPT) 
The effect of ACBP on spatial and emotional learning and memory was further analysed with LPT. Field 
EPSP waveforms evoked by Schaffer-collateral stimulation were measured in CA1 during the baseline 
recording period. Comparable stimulation currents elicited equivalent amplitude responses in tg and sg 
slices and no differences in responses were observed between the groups in any parameter tested 
(amplitude, slope, half-width; n.s)(Paper I, Table 1). 
 
Theta burst stimulation led to a transient post tetanic potentiation up to three minutes in both sg and tg 
mice. In contrast, it evokes to a long-term potentiation of synaptic strength only in sg but not in tg mice. 
In sg mice, Schaffer-collateral synapses exhibited approximately 100% increase in EPSP amplitude 
measured 10-45 minutes after high frequency stimulation, whereas the potentiation was approximately 
20% in DBI tg mice during this time period (Paper I, Fig. 7). There was no difference between the sexes 
(for gender effect F=0.06, n.s.). Thus, there were significant differences in the long term potentiation of 
EPSP amplitude between female tg and sg mice (for group effect F=5.20, p<0.05) and between male tg 
and sg mice (for group effect F=6.13, p<0.05). In all mice, there were significant differences in the long-
term potentiation of EPSP amplitude between tg and sg mice (for group effect F=11.21, p<0.01)(Paper I, 
Fig.7). 
5.3.4 Seizure induction 
In order to investigate in more detail the possible effect of ACBP on GABAA receptor function, i.c.v 
injections of KA and PTZ were performed. All mice, except one sg female treated with 30 mg/kg of KA, 
developed seizures during the four hour observation period (Paper I, Table 2). The highest mortality 
(38.5%) in tg mice occurred at 28 mg/kg. In sg mice, the highest mortality (58.3%) was seen at 30 
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mg/kg. The time period from injection to death was longest at the lowest dose 26 mg/kg used in both tg 
and sg animals. The time became shorter as the dose was increased in tg mice but this was not observed 
in sg animals, however the difference was not statistically significant. Furthermore, there were no 
significant differences between sg and tg mice in the total numbers of seizures or in the latency to first 
seizure during the 4-hr observation period (Paper I, Table 3). There was no difference in the amount of 
degenerating neurons in granule, hilus, CA3a, CA3b, CA3a and CA1 areas (Paper I, Table 4).  
 
All mice injected with 60 mg/kg PTZ developed seizures. Sg animals had even higher mortality (37%) 
than tg mice (0%) but there were no statistical differences in either the number or the time period to the 
first seizure. 
5.4 Phenotype of the rat line 
5.4.1 Weight 
It has been shown that ODN, a processing product of ACBP can influence the weight and food intake of 
rodents (de Mateos-Verchere et al., 2001). In our tg animals, no weight difference was observed when 
these rats were compared sg littermates at the age 6 weeks (188±25 g for sg versus 169±35 g for tg) or at 
the age of 1 year (515±29 g for sg versus 524±25 g for tg). During the four week period on the MC or 
LC high fat diets, the weight of the animals was monitored. There was no significant difference between 
tg and sg rats within the same diet group. 
5.4.2 Food intake 
The daily food consumption was measured for four days. The mean daily food intake (in grams) was not 
affected by the increased ACBP expression (19.8 ± 1.7 g for sg versus 18.8±2.5 g for tg). Taking into 
account the weight of the animals did not influence the results. 
5.4.3 Acyl-CoA levels 
It has been shown that overexpression of ACBP increases the acyl-CoA content of yeast and mouse liver 
(Huang et al., 2005; Knudsen et al., 1994). To ensure that mouse ACBP gene was functionally active in 
rats and to study whether overexpression of ACBP could affect acyl-CoA contents, we measured acyl-
CoA levels from visceral adipose tissue, liver and brain of fed and fasted animals. Our results 
demonstrate that the mouse ACBP gene is functionally active in rats: liver C16 acyl-CoA levels were 
increased (C16:0 2.8 times and C16:1 2.3 times higher) as well as the C20 levels (C20:0 1.4 times and 
20:4 1.3 times higher) in fed animals. There was no difference in any of the liver acyl-CoAs measured 
from fasted animals (Paper II, Fig.2, note the different scale). In adipose tissue, there was a 5 to 11 times 
increase in C16:0, C16:1 and C18:1 in the fed state. In fasted animals, levels of C16:0, C16:1, C18:0 and 
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C18:1 were 2 to 4 times higher in tg animals (Paper II, Fig.2). In brain there was an increase of C20:4 in 
the fed tg rats. Interestingly, the fasted tg rat had an decrease in C20:0 levels compared to sg littermates 
(Paper IV, Fig.2). 
5.4.4 Free fatty acids, triglycerides and cholesterol 
Overexpression of ACBP did not influence serum free fatty acid, plasma triglyceride and cholesterol 
levels of tg rats fed with standard diet (Paper II, Table 2). In addition, high ACBP expression did not 
affect the free fatty acid levels of tg rats fed with either medium or long chain high fat diets. 
5.4.5 Glucose tolerance 
GTT was performed to test whether overexpression of ACBP and/or the subsequent changes with 
increased levels of cellular acyl-CoAs affect plasma glucose levels or insulin secretion. There was no 
significant difference between tg rats and their sg controls in the glucose tolerance or in the insulin levels 
when fed with normal diet (Paper II, Fig.3). 
 
GTT was also performed after feeding a MC and LC high fat diet for four weeks. The MC diet fed tg 
animals had improved glucose tolerance (ANOVA p=0.0036. Paper III, Fig.2), and a significant 
reduction in overall insulin levels (ANOVA p=0.016). The insulin levels were significantly lower at 20 
min and 120 min (p< 0.05. Paper III, Fig.2) indicative of an improved insulin responsiveness. In LC diet 
fed animals, there was no difference in glucose tolerance or in the insulin levels (Paper III, Fig.2).  
5.5 Gene regulation 
5.5.1 Peroxisome proliferator-activated receptors 
To study the effects of ACBP overexpression on regulators of metabolic responses, mRNA levels of 
transcription factors PPAR ,  and  were measured in liver and adipose tissue of tg and sg animals in 
different metabolic states: fed and fasted state and after feeding high fat diets with MC or LC fatty acids 
for four weeks. In fed tg animals, expression of liver PPAR  and PPAR  mRNA was down-regulated by 
82% and 62% respectively compared to sg littermates (Paper II, Fig.4), whereas there was no significant 
difference in PPAR  mRNA levels. In adipose tissue, there was a decrease in PPARγ by 23% and by 
43% in PPARδ levels (Paper II, Fig.4). 
 
In contrast, fasting significantly increased the expression of all liver PPARs by 2 to 7 times in tg rats 
(Paper II, Fig.4a), while in sg rats there was simply a trend to higher expression of PPAR , but there 
was no change in the PPARγ and δ levels. In adipose tissue, PPAR  levels were reduced by 70% in 
fasted syngenic rats, while expression was increased by 37% in the tg littermates. The expression of 
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PPAR  was significantly increased (3.3 times) by fasting in tg rats, but remained unchanged in the sg 
controls (Paper II, Fig.4b). Fasting abolished the difference in liver PPARγ and δ expression levels 
between tg and sg animals. On the contrary, in adipose tissue, fasting evoked higher PPAR γ and δ 
expression in tg animals when compared to their sg controls. 
 
Furthermore, dietary factors can influence the PPAR expression. Expression of liver PPARα or PPARγ 
in sg animals did not change under the MC compared to the LC diet, but liver PPARδ levels were 
increased in MC diet fed sg rats compared to the LC diet (Paper III, Fig.3). The tg rats fed with the MC 
diet had decreased expression levels of liver PPARα and PPARγ when compared to the LC diet fed 
animals and no change in PPARδ. Tg animals fed with the LC diet had 2 to 3 times higher levels of liver 
PPAR mRNA expression than their sg littermates fed with the same diet. In the MC diet group, tg rats 
had significantly reduced (by 43%) levels of liver PPARγ when compared to sg controls. In adipose 
tissue, there were no significant changes in PPARγ or PPARδ expression between MC and LC diet fed tg 
or sg animals. The MC diet fed tg rats displayed significantly increased (by 31%) levels of PPARγ 
compared to the sg animals fed with the same diet (Paper III, Fig.3). 
5.5.2 Sterol regulatory element-binding proteins 
Another metabolic regulator known to be involved in ACBP and PPAR regulation is SREBP (Fajas et 
al., 1999; Neess et al., 2006; Swinnen et al., 1998). The effects of ACBP overexpression on SREBP-1 
mRNA was measured from liver and adipose tissue. Expression of SREBP-1 mRNA was down-regulated 
by 77% in liver and by 23% in adipose tissue (Paper II, Fig.5). In sg rats, fasting reduced the SREBP-1 
mRNA levels in both liver and adipose tissue. In tg animals, fasting reduced SREBP-1 mRNA levels 
only moderately and only in liver (Paper II, Fig.5). 
 
The differences in SREBP expression were also investigated in response to the diets with the sg and tg 
animals having a lower liver SREBP-1 expression when fed with the MC diet compared to the LC diet. 
The tg rats fed with the MC diet exhibited decreased levels (by 35%) of liver SREBP-1 compared to sg 
controls. On the contrary, after the LC diet tg rats had 1.5 times higher SREBP-1 levels compared to 
their sg littermates (Paper III, Fig.3). In adipose tissue, both sg and tg animals had similar levels of 
SREBP-1 expression when on the MC diet. Tg animals fed the LC diet had increased SREBP-1 levels 
when compared to sg controls (Paper III, Fig.3), in sg rats, SREBP-1 expression was unchanged. 
5.5.3 AMP-activated protein kinase 
SREBP-1 and PPARs have been demonstrated to be regulated by AMP-activated protein kinase (AMPK) 
(Leff, 2003; Zhou et al., 2001). Therefore, we determined protein levels of the  subunit of AMPK in the 
liver of fed rats. The levels of total AMPKα and its active form, Thr 172 phosphorylated AMPKα, were 
significantly elevated in the liver tissue of tg rats (Paper II, Fig.6). Furthermore, intraperitoneal  
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Table 4. Summary of the effects of nutritional state and ACBP on PPAR and SREBP-1 
mRNA expression and AMPK protein levels. 
 
 tg compared to 
sg in fed state 
tg compared to 
sg in fasted state 
fasted compared 
to fed in sg 
fasted compared 
to fed in tg 
Liver     
PPAR  no change no change no change + 
PPAR  - no change no change + 
PPAR  - no change no change + 
SREBP-1 - no change - - 
AMPK +    
Adipose tissue     
PPAR  - + - + 
PPAR  - + no change + 
SREBP-1 - no change - no change 
 
 
+ up-regulation,  - down-regulation 
 
 
 
 
 
 
 
 
Table 5. Summary of the effects of high fat diets and ACBP on PPAR and SREBP-1 
mRNA levels and AMPK protein levels.  
 
 
MC compared 
to LC in sg 
MC compared 
to LC in tg 
tg compared to 
sg in MC 
tg compared to 
sg in LC 
Liver     
PPARα no change - no change + 
PPARγ no change - - + 
PPARδ + no change no change + 
SREBP-1 - - - + 
AMPK   no change - 
Adipose tissue     
PPARγ no change no change + no change 
PPARδ no change no change no change no change 
SREBP-1 no change no change no change + 
 
+: up-regulation,  -: down-regulation, 
MC: medium chain high fat diet, LC: long chain high fat diet 
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injectionsof the AMPK inhibitor, compound C, to tg rats resulted in 17% reduction in protein levels of 
Thr 172 phosphorylated AMPKα (Paper II, Fig.7a), while quantitative real-time PCR analysis of 
SREBP-1 and PPARs detected a 2.2 fold increase in SREBP-1 mRNA expression in compound C treated 
tg animals with no difference in PPARγ nor PPARδ mRNA levels (Paper II, Fig.7b).  
 
The effect of the two high fat diets on the AMPK levels was also investigated. There was no difference 
in AMPK protein levels between MC and LC diet fed animals. In the LC diet fed group, tg animals had 
48% lower (p=0.02) protein levels of AMPKα than their sg littermates (Paper III, Fig.4). 
5.5.4 Gene expression in the hypothalamus 
The changes in mRNA expression of several transcription factors known to be involved in hypothalamic 
or peripheral regulation of fatty acid metabolism and two key enzymes participating in hypothalamic 
fatty acid induced food intake regulation were measured from fed and fasted animals. In the fed state, the 
tg rats had a reduction in the expression levels of FAS (Paper IV, Fig.3), sirtuin-1 (SIRT-1) and PPARδ 
(Paper IV, Fig.4) when compared to sg controls. In addition, the tg animals had an increase in the mRNA 
levels of CPT-1c (Paper IV, Fig.3). Fasting increased the SIRT-1 expression of the tg rats, while it did 
not influence the expression of the sg animals nor alter the expression of PPARδ, FAS or CPT-1c of the 
tg animals. On the contrary, the sg rats displayed decreased FAS levels and increased CPT-1c expression 
after fasting, but no change in PPARδ expression. There were no difference in the expression of SREBP-
1 between tg and sg animals in either the fed or fasted state, both tg and sg rats showed a fasting induced 
reduction in SREBP-1 levels (Paper IV, Fig. 4). 
5.5.5 AMP-activated protein kinase in the hypothalamus 
The possible role of AMPK, a known regulator of hypothalamic food intake, was investigated. The 
protein levels of both total AMPKα and the active form, Thr 172 phosphorylated AMPKα were 
measured from hypothalamus of fed tg rats and sg littermates. There were no significant differences in 
the total AMPKα or the phosphorylated AMPK  levels between tg and sg animals (Paper IV, Fig.5). 
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6. DISCUSSION 
6.1 ACBP gene and animal models 
Acyl-CoA binding protein (ACBP) / diazepam binding protein (DBI) is a 10 kDa protein ubiquitously 
expressed throughout the whole body. Many different functions have been associated with this protein. 
ACBP can displace diazepam from type A γ-aminobutyrate receptors (GABAA receptors) (Guidotti et al., 
1983) and modify the function of peripheral benzodiazepine receptors (PBR) (Bovolin et al., 1990; 
Garnier et al., 1993; Papadopoulos et al., 1992). In addition to its effects on the benzodiazepine 
receptors, the ability to bind and act as a pool former and transporter of acyl-CoAs is one of the best 
recognized functions of ACBP (Rasmussen et al., 1990; Rosendal et al., 1993). Although there are a 
plethora of reported effects, the precise function of ACBP in the physiology of mammalians remains 
unclear. Previous studies have been conducted mainly with cells, or they have utilized exogenous 
administration of the protein to investigate the short term effects of ACBP. Huang et. al. (2005) utilized 
transgenic mice overexpressing ACBP focusing only on changes in the liver fatty acid composition of 
these mice. Importantly ACBP cDNA expression was controlled by a phosphoglycerate kinase promoter, 
which does not allow endogenous regulation of ACBP (Huang et al., 2005). Therefore we were 
interested to investigate the role of ACBP in rodent physiology and regulation gene expression. We 
utilized a construct containing the entire mouse ACBP gene under the gene’s own 1.8 kb promoter 
region to allow endogenous expression of the transgene. 
 
We isolated the mouse ACBP/DBI gene from a genomic library of mouse strain 129/SvJ and utilized the 
isolated gene to create mouse and rat lines with constant overexpression of ACBP. The isolated mouse 
ACBP gene (AF220221) consisted of a 1.8 kb promoter, 4 exon regions including the recently found 
alternative exon 1 (Nitz et al., 2005) and a 1.9 kb flanking region. No differences to the published cDNA 
sequences could be detected. Furthermore, the isolated gene contained all of the so far published 
regulatory regions of the mouse ACBP gene. The isolated mouse ACBP gene allowed us to create a 
mouse line expressing high levels of native ACBP. The mouse ACBP gene was additionally utilized to 
create a rat line with high levels of ACBP. The mouse and rat ACBP protein sequences are 98.8% similar 
and reports on the regulation of ACBP gene transcription regulation have found no major differences 
(Helledie et al., 2002a). The basic characterization of both mouse and rats lines demonstrated that the 
transgene was overexpressed in all tissues studied. In the central nervous system of mice, the transgene 
was found to be expressed in the same locations as previously reported for the endogenous protein (Costa 
and Guidotti, 1991; Yanase et al., 2001) The mouse ACBP gene was also functional in rats, since 
elevated levels of mouse ACBP increased the acyl-CoA pool of tg rats. Both transgenic mouse and rat 
lines were viable and fertile. We utilized a rat line overexpressing ACBP as rats are more easily 
subjected to surgical manipulation and tissue preparation. In addition, the genetic background of the 
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mouse line utilized (F1 cross of Balb/c x DBA/2) was unsuitable for the intended metabolic studies, 
resulting most likely from the fact that high metabolic rate of DBA/2 strain (Pennycuik, 1967) was 
randomly mixed within the metabolic background of Balb/c strain. 
6.2 ACBP in central nervous system 
Our results from a mouse line overexpressing the mouse ACBP gene clearly demonstrate that long-term 
elevation of ACBP levels does not cause anxiety or any pro-conflict behaviour, in contrast to published 
data (Guidotti, 1991). Previous studies have investigated mainly the short term effects of ACBP and its 
processing products (Kavaliers and Hirst, 1986), while in our animals, the expression levels were 
chronically elevated. Since acute administration of ACBP has been suggested to have a modulatory 
effect on the GABAA receptors and PBRs, it is logical that the long term endogenous expression of 
ACBP would recruit adoptive processes. GABAA receptor signalling is important for neural signalling 
and therefore its function is under tight regulation. Results from the experiments on benzodiazepine 
stimulation of peripheral benzodiazepine receptors (PBR) provide further evidence for compensation of 
the long-term effects. These studies indicate that the acute and chronic effects of PBR ligands are quite 
different. Acute administration of PBR ligands evoked increased steroid levels in both rats and humans, 
whereas chronic treatment with PBR ligands did not affect circulating steroid levels of female rats 
(Lacapere and Papadopoulos, 2003). One possible mechanism to adapt to the chronic effects of ACBP is 
down-regulation of SREBP-1. SREBP-1 up-regulates the expression of steroidogenic acute regulatory 
protein (StAR), a protein involved in cholesterol transport to PBR (Lacapere and Papadopoulos, 2003). 
This indicates that although increased ACBP levels activated PBR it also caused a down-regulation of 
StAR levels, resulting in reduced cholesterol transport to PBR. In agreement, in our transgenic animals 
there were no changes in the plasma levels of cholesterol. Interestingly, we detected a reduction only in 
the liver and adipose tissue SREBP-1 mRNA levels, but not in the hypothalamus, yet this does not rule 
out the possibility that SREBP-1 could be affected in other brain regions. To further investigate the role 
of ACBP in neural signalling, we performed seizure threshold experiments with KA and PTZ. There was 
no difference in the KA induced seizures between tg and sg controls in the number, severity or duration 
of the seizures and the administration of KA did not evoke any changes between tg and sg mice in the 
histology preparations performed after the seizures. In the CNS, KA activates kainate receptors, which 
have been shown to down-regulate GABAergic inhibition (Clarke et al., 1997; Michaelis, 1998). Due to 
the similarities in the seizure behaviour and pathology evoked by KA and epilepsy, this compound has 
been utilized as a model of temporal lobe epilepsy. Our results indicate that either ACBP does not 
influence the mechanism by which KA induces seizures or the continually elevated levels can activate 
compensatory mechanisms that abolish the effects of ACBP. Elevated plasma ACBP levels have been 
detected from a subgroup of patients suffering from epilepsy (Ferrarese et al., 1998). Chronic 
overexpression of ACBP by itself or with KA did not evoke any differences in the seizure activity, 
indicating that ACBP has a modulatory role. Furthermore, i.c.v injections of PTZ is another well-
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established seizure model. The actions of PTZ are mediated by its antagonistic action on the GABAA 
receptors. Similar results were obtained with the PTZ injections as seen in the KA studies, i.e. 
overexpression of ACBP did not affect the seizures. In contrast to the KA results, there was a difference 
in the PTZ induced mortality, sg animals had even a higher mortality (37%) than the tg mice (0%). 
Similar results have been reported by Garcia de Mateos-Verchere et al. (1999), i.c.v administration of 
ODN (100 ng for mice) prior to PTZ (100 mg/kg, i.p.) injections reduced the mortality by 30%. These 
results suggest that ODN/ACBP influence the function of GABAA receptors in a way that reduces the 
ability of PTZ to block Ca
2+
 channels, but do not prevent it completely. The mechanism by which ACBP 
reduces mortality requires further investigation on the role of ACBP in GABAA receptor and PBR 
regulation.  
 
Behavioural and learning aspects of ACBP overexpressing mouse were studied in behaviour tests and 
long-term potentiation (LTP). Our results from LTP experiments show that elevated levels of ACBP 
could affect the development of long-term synaptic plasticity in the CA1 area of hippocampus. The tg 
mouse exhibited decreased plasticity in the excitatory synapses without any changes in the inhibitory or 
excitatory synaptic transmission. ACBP has been reported to have an inhibitory effect on the GABAA 
receptors (Costa and Guidotti, 1991), therefore overexpression of ACBP should increase rather than 
decrease the excitatory response. The molecular reasons for these unexpected findings are unclear and 
require further investigations. The observed decrease in LTP might be due a reduction in NMDA 
receptor activity. The excitatory response in LTP is known to be dependent on the activation of NMDA 
receptors (Larson and Lynch, 1988) and NMDA receptor activation can increase the ACBP mRNA 
expression in cerebral cortical neurons (Katsura et al., 2001). Behaviour tests confirmed that high 
expression levels of ACBP did not affect the basic behavioural pattern of the animals. Nevertheless, 
changes in the LTP were projected on the animals, tg mice had reduced freezing in the conditioning 
context. These results indicated that ACBP overexpression influences the hippocampus-dependent 
learning and memory. 
 
In addition, we detected that the overexpression of ACBP lead to enlargement of the lateral ventricles. 
This phenomenon was evident at birth and in both transgenic mice and rats, indicating that it is specific 
effect of ACBP overexpression. One possible explanation might be perivascular astrocytosis. This 
process has been shown to be the cause of hydrocephalus in other models (Crews et al., 2004) and in 
addition Alzheimer type II astrocytosis has been associated with increased levels of ACBP (Butterworth 
et al., 1991). The precise influences and the development method of these enlarged lateral ventricles will 
require further investigation, as well as the possible role of ACBP in the pathology of Alzheimer’s 
disease.  
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6.3 ACBP and hypothalamic regulation of food intake 
Hypothalamus and particularly the arcuate nucleus in the hypothalamus are considered to be one of the 
main sites for regulation of energy homeostasis and food intake. The involvement of nutrients and 
especially the role of fatty acids in the hypothalamic regulation of food intake have attracted considerable 
attention. Recent studies have shown that fatty acids or more specifically their esters, acyl-CoAs are 
involved in appetite regulation (Lam et al., 2005a; Obici et al., 2002). The hypothalamic pool of acyl-
CoA can be formed either from fatty acid entering the cells or by endogenous synthesis. Peripheral 
administration of long chain fatty acids elevated the hypothalamic long chain acyl-CoA pool size (Lam 
et al., 2005a). In addition, all of the components required for the intracellular synthesis and oxidation of 
acyl-CoAs are expressed in neurons at a relatively high level. Some of the main components of the acyl-
CoA synthesis or oxidation, including FAS, CPT-1 and AMPK have been associated with regulation of 
food intake in the hypothalamus (Lam et al., 2005b). Interestingly, the functions of all three enzymes are 
closely link to each other, they all are involved in acyl-CoA pool size regulation. Although fatty acids, 
especially acyl-CoAs, are associated with hypothalamic regulation of food intake, little is known about 
the role of proteins that bind acyl-CoAs, namely fatty acid binding proteins (FABPs) and ACBP. The 
hypothalamic levels of ACBP have been found to be among the highest in central nervous system, and 
ACBP expression in hypothalamus is concentrated in the nerve terminals of the arcuate nucleus and 
median eminence (Alho et al., 1985; Alho et al., 1988). In addition, previous studies utilizing the 
processing product ODN have indicated that it is involved in the regulation of food intake in a receptor 
mediated manner. Furthermore, i.c.v injection of ODN has been shown to reduce food intake in rodents. 
The action of ODN was found to be mediated through metabotropic receptors positively coupled to 
phospholipase C via a pertussis toxin-sensitive G protein (de Mateos-Verchere et al., 2001; do Rego et 
al., 2007). Furthermore, Compere et al. (2006) has suggested that ACBP might be involved in appetite 
control caused by androgens. This study demonstrated that androgens and glugocorticoids up-regulated 
the ACBP mRNA expression in hypothalamus of male mice. 
 
Although these previous results indicate that ACBP might play a role in the regulation of food intake our 
results from ACBP transgenic rats demonstrated that there was no difference in the daily food intake or 
in the weight of the tg and sg animals. In addition, there was no difference in the weight of old rats (1 
year old) indicating that there are no differences during the life span of the animals that could become 
manifested as an accumulatory difference in weight. These results suggest that long term overexpression 
of ACBP does not influence the food intake, but do not exclude the possibility that ACBP can function 
as a short term modulator. It is likely that the hypothalamic acyl-CoA pool is under tight regulation that 
does not allow drastic changes. In accordance, further investigation of our ACBP overexpressing rat line 
demonstrated that there were only slight changes in the brain acyl-CoA pool. Fed tg animals had 
increased levels of C20:4 and the fasted tg rats had decreased levels of C20:0. Huang et. al. (2005) 
reported that in liver, ACBP can influence the acyl-CoA pool size in terms of chain length and saturation 
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dependent manner. This was suggested to be caused by variation in ACBPs ability to bind different acyl-
CoAs forms and changes in the activity of acyl-CoA utilizing enzymes. Our transgenic rats had 
significant changes in the hypothalamic gene expression pattern: The mRNA levels of two known 
regulators food intake and acyl-CoA pool were differentially expressed in tg and sg rats. The expression 
of FAS was reduced and the levels of CPT-1c were elevated in the fed tg animals. The reduction of FAS 
results into decreased acyl-CoA production and increased accumulation of malonyl-CoA, an important 
inhibitor of CPT-1. Decrease in function and expression levels of FAS are associated with a reduction in 
food intake (Lopez et al., 2006; Shimokawa et al., 2002). On the contrary, increased CPT-1c levels have 
been associated with increased food intake (Obici et al., 2003; Wolfgang et al., 2006). Elevated CPT-1c 
levels do not influence the acyl-CoA pool considerably, since the protein is unable to transport the acyl-
CoAs into mitochondria (Wolfgang et al., 2006). Nevertheless, CPT-1c is able to bind malonyl-CoA and 
affects the food intake and weight control. Wolfgang et al. (2008) have shown that mouse line with 
knock-out of CTP-1c exhibit decreased food intake and lower body weight, without any changes in the 
gene expression or in the malonyl-CoA and acyl-CoA levels. The exact role of CPT-1c in the appetite 
control remains unclear. Wolfgang et al. (2008) suggest that CPT-1c has rather a regulatory than a 
metabolic role, as the malonyl-CoA and acyl-CoA levels remained constant, yet a metabolic role cannot 
be excluded since acyl-CoA levels were measured from hippocampus, not hypothalamus (Wolfgang et 
al., 2008). Therefore, in hypothalamus CPT-1c might be able to release the other hypothalamic forms of 
CPT-1 (namely CPT-1a) from inhibition caused by malonyl-CoA. The decrease in FAS expression and 
increase of CPT-1c expression might provide a possible mechanism for the unchanged food intake of the 
tg animals. To further investigate these changes we measured the mRNA levels of transcription factors 
are involved as well as the protein levels of AMPK. Our fed tg animals had reduced levels of PPAR  and 
SIRT-1 mRNA in the hypothalamus. There was no previous data on the actions of these transcription 
factors in the food intake regulation. In peripheral tissues, it seems that PPAR  is involved in the 
regulation of FAS in liver and the liver and muscle isoforms of CPT-1 in muscle tissue (Barish et al., 
2006; Lee et al., 2006). These previous data combined with our results suggest that PPAR  is involved in 
FAS regulation also in hypothalamus. PPAR  up-regulates FAS (Lee et al., 2006), hence a reduction 
PPAR  levels may contribute to the observed reduction in hypothalamic FAS levels. The increased CPT-
1c levels cannot be explained by the reduced PPAR  levels, but one possible mechanism might be the 
reduced levels of SIRT-1, a transcription factor involved in glucose metabolism. SIRT-1 has been shown 
to regulate peripheral forkhead box O1 (FOXO1) transcription factor, which in turn increases food intake 
in rodents (Nakae et al., 2008; Yang et al., 2006). Our results from the ACBP overexpressing rats 
demonstrate that constantly high levels of ACBP do not affect the food intake. The tight regulation of 
hypothalamic acyl-CoA pool size evoked changes in the gene expression profile that may provide a 
possible preventive mechanism. Based on our results, we cannot rule out a short term modulatory effect 
of ACBP. The results on the actions of ODN injections point to this possibility, acute administration 
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reduced food intake of mice and rats but over the long term, the effects were diminished (de Mateos-
Verchere et al., 2001). 
6.4 ACBP and physiology of rats 
We utilized our rat line overexpressing mouse ACBP to study the physiological effects of constantly 
high levels of ACBP. In accordance with previous results from yeast, cell lines and mouse liver (Huang 
et al., 2005; Knudsen et al., 1994; Yang et al., 2001) we observed increased acyl-CoA levels in liver and 
in addition in adipose tissue of our tg rats. Our results clearly demonstrate that the increased levels of 
ACBP influenced the acyl-CoA pool in a specific manner. The variation in ACBPs binding affinity 
toward different acyl-CoA forms and the ability to enhance further utilization of different acyl-CoA 
forms can, in part, explain the selective nature of the acyl-CoA increase (Faergeman et al., 1996; Huang 
et al., 2005; Jolly et al., 2000). In addition, our results show that the effects of ACBP on the acyl-CoA 
pool were dependent on the nutritional state (fed/fasted) of the animals and on the tissue studied. 
Previous studies have shown that fasting can influence the intracellular acyl-CoA pool (Woldegiorgis et 
al., 1985) and the differential metabolic usage of fatty acids and acyl-CoAs in different tissues may be 
another explanation for our results. On the contrary to the acyl-CoAs, we did not observe any changes in 
the serum free fatty acid levels or in the plasma triglyceride or cholesterol levels. Huang et al. (2005) 
reported that mice overexpressing ACBP under the control of a phosphoglycerate kinase promoter had 
increased liver triglycerides and phospholipids while the cholesterol levels were unchanged, but these 
tissue levels are not comparable with circulating levels.  Furthermore, high ACBP levels in combination 
with either MC or LC diets did not induce any changes in the serum free fatty acid levels between tg and 
sg rats.  
 
Acyl-CoAs and ACBP have been claimed to be involved in insulin secretion, ACBP is believed to inhibit 
glucose stimulated insulin release and acyl-CoAs can influence several key players of signal transduction 
in β-cells (Corkey et al., 2000; Ostenson et al., 1990). Nonetheless, we did not detect any differences in 
the GTT or in the insulin levels during the test between normally fed sg and tg rats. In accordance, it has 
been shown that ACBP mainly affected the acute phase of glucose stimulated insulin release and that in 
long term experiments, it had only limited effects (Ostenson et al., 1994; Sjoholm et al., 1991). On the 
contrary, when the tg rats were challenged with a MC diet we found that high levels of ACBP improved 
the glucose tolerance, tg rats displayed lower blood glucose in combination with reduced insulin levels. 
When the animals were challenged with a LC diet, no differences between tg rats and the controls were 
observed. Our results indicate that in animals fed with standard rodent diet or LC diet overexpression of 
ACBP either did not influence the glucose tolerance or its actions were prevented. On the other hand, our 
results also indicated that ACBP might play a role in the improved insulin sensitivity observed in the 
medium chain high fat diet versus long chain high fat diet fed animals (Han et al., 2003; Takeuchi et al., 
2006), i.e. high levels of ACBP appears to have a beneficial role in the MC diet fed rats. The MC and LC 
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high fat diets utilized in our study were specially designed to have low energy content allowing the 
investigation chain length specific effects of fatty acids, therefore our results and results obtained by Han 
et al. (2003) and Takeuchi et al. are not directly comparable. The mechanisms preventing changes in 
GTT of standard diet and LC diet fed tg rats and the ACBP induced changes that might improve glucose 
tolerance in the MC diet fed animals were further characterized by determining the effects of ACBP on 
gene expression regulation.  
6.5 ACBP and regulation of gene expression 
The effect of constant ACBP overexpression on the mRNA levels of transcription factors regulating lipid 
and glucose metabolism were measured from liver and adipose tissue of rats. In addition, the effects of 
nutrition state (fed/fasted) and diets (MC and LC high fat diets) were investigated. Furthermore, a protein 
levels of AMPK, a well-known regulator of cellular metabolism, was determined from the livers of the 
animals fed with either standard diet or high fat diets with either MC or LC fatty acids.  
6.5.1 PPARs 
ACBP had the least effect on PPAR . Only in the LC diet fed animals there was a difference between tg 
and sg animals in the expression levels of PPAR , with tg rats having significantly elevated levels 
compared to sg littermates. In contrast to PPAR , ACBP seems to affect the mRNA expression of the 
other isoforms of the PPAR transcription factor family. Accordingly, previous studies have shown that 
ACBP is able to inhibit the trans-activation of PPARs at the protein level (Helledie et al., 2000; Helledie 
et al., 2002b). In the fed state, the tg rats displayed reduced levels of PPAR  and PPAR  in both liver and 
adipose tissue. The reduction of the fed state expression of PPAR  and PPAR  points to increased 
accumulation of fatty acids, as PPAR  is known to stimulate lipid storage in adipose tissue and PPAR  is 
involved in fatty acid oxidation. Accordingly, our tg animals exhibited increased acyl-CoA levels. 
Fasting influenced the animal’s response to ACBP, it abolished the differences in PPAR  and PPAR  
expression levels in the liver and in adipose tissue it evoked increased expression in tg rats. It seems that 
the regulatory elements activated by fasting are a stronger stimulus for PPAR  and PPAR  transcription 
than ACBP, or the consequences of increased levels of ACBP are prevented in such a manner that it is 
active only in the fasted state. The fact that the acyl-CoA pool of the animals was also affected in a 
fed/fasted state dependent manner suggests that acyl-CoAs might underlie the influence of ACBP on 
PPARs. It has been shown that acyl-CoAs can affect the activity of PPARs in a chain length specific 
manner (Faergeman and Knudsen, 1997; Schroeder et al., 2008). Furthermore, the involvement of other 
regulatory factors like AMPK cannot be ruled out. In addition to fasting, both MC and LC diets affected 
the ACBP induced regulation of PPAR  and PPAR . The LC diet fed tg animals had increased liver 
PPAR  and PPAR  levels, while the MC diet evoked reduced PPAR  expression in the liver and 
increased expression in adipose tissue of tg rats. Previous studies have indicated that medium and long 
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chain high fat diets can control the expression of PPARs and other transcription factors in different ways 
(Han et al., 2003; Takeuchi et al., 2006), although there have been discrepancies in the results obtained. 
Han et. al. (2003) reported that medium chain high fat diet fed rats had reduced adipose tissue PPAR  
levels compared to long chain high fat diet, while Takeuchi et. al. (2006) detected an increased 
expression of PPAR . Our results demonstrate that there were no difference in adipose tissue PPAR  
expression between MC and LC diet fed sg animals, while the tg rats had reduced PPAR  levels 
compared to sg littermates. In addition to chain length specific effects of the fatty acids used (Faergeman 
et al., 1996; Huang et al., 2005; Jolly et al., 2000), the fact that our diets energy content is not 
comparable with the diets used by Takeuchi et al. (2006) and Han et al. (2003) might explain the 
differences in dietary responses. We utilized high fat diets with low energy content (Table 1) to be able 
to focus on the effect of fatty acid chain lengt. Our results from LC diet suggest that tg animals exhibited 
increased lipid metabolism, as the expression levels of the transcription factors and ACBP were elevated. 
Results from the MC diet fed animals demonstrate that the effect of ACBP on the PPAR  mRNA levels 
might be responsible for the improved glucose tolerance of MC diet fed tg rats. The down-regulation of 
liver PPAR  levels leads to decreased liver lipid accumulation, which is accompanied by elevated lipid 
storage in adipose tissue resulting from increased PPAR  expression.  
6.5.2 SREBP-1 
SREBP-1 is another transcription factor known to be involved in the regulation of both ACBP and 
PPARs (Fajas et al., 1999; Neess et al., 2006; Swinnen et al., 1998). In fed animals, overexpression of 
ACBP resulted in decreased levels of liver and adipose tissue SREBP-1 mRNA. Fasting abolished the 
difference between tg and sg animals in both of the tissues studied. These results are in accordance with 
the results obtained from PPAR  and PPAR . Changes in the intracellular acyl-CoA contents might be 
responsible for the decreased SREBP-1 levels as unsaturated fatty acids can reduce SREBP-1 mRNA 
levels (Jump et al., 2005). The involvement of additional regulatory factors cannot be ruled out, for 
example liver X receptor (LXR) , a known regulator of SREBP-1, which has been reported to act in a 
nutritional state dependent manner (Eberle et al., 2004). SREBP-1 expression was elevated in the LC diet 
fed and decreased in the liver of MC diet fed tg rats. In contrast to the effect of the diets on PPAR 
expression, also the adipose tissues expression of SREBP-1 was increased in the tg rats fed with the LC 
diet.  
6.5.3 AMPK 
The protein levels of the catalytic  subunit of AMPK were determined to further investigate how ACBP 
can influence the regulation of transcription factors. AMPK is known to be involved in the 
phosphorylation mediated regulation of both PPARs and SREBP-1 (Leff, 2003; Zhou et al., 2001). The 
fed tg rats had elevated levels of both total AMPK  and the active, Thr 172 phophorylated, form in their 
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livers. In addition, we detected that in the liver of LC diet fed rats, overexpression of ACBP decreased 
the levels of total AMPK . These changes in the AMPK  levels are in accordance with the observed 
changes in the expression levels of PPARs and SREBP-1, indicating that the regulatory effects of ACBP 
might be mediated through AMPK. To further investigate this possibility, we utilized intraperitoneal 
injections of a specific inhibitor of AMPK (compound C). The results demonstrated that injections of 
compound C significantly elevated the mRNA levels of SREBP-1 in fed tg animals, while there was no 
change in the expression levels of PPARs. This indicates that regulation of SREBP-1 is mediated through 
AMPK, while the effects of ACBP on PPARs are independent of the AMPK activity. Further support for 
a role for AMPK in the effects of ACBP on SREBP-1 expression was obtained in hypothalamus where 
there were no differences in the AMPK  levels between tg and sg animals. In accordance, also SREBP-1 
mRNA expression remained unchanged. Our results also reveal that the acyl-CoA form of palmitate 
(C16:0) was elevated in both liver and adipose tissue of tg animals, increased levels of palmitate have 
been shown to activate AMPK (Wang et al., 2007; Watt et al., 2006). In addition, the C16:0 levels are 
normally elevated by fasting, providing a possible explanation for the nutritional state specific effects. In 
the brain tissue, there were no changes in the AMPK  levels and the overexpression of ACBP did not 
influence the C16:0 pool size. This suggests that the elevated acyl-CoA levels of ACBP overexpressing 
animals affect SREBP-1 expression through an increased activity of AMPK. 
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7. SUMMARY 
The principal aim of this study was to investigate the physiological role of acyl-CoA binding protein 
(ACBP) / diazepam binding protein (DBI) in two rodent models. ACBP has been associated with various 
functions, some of which are proposed to be mediated mainly through processing products of the native 
protein. Therefore, we have utilized a construct that allows endogenous regulation of the gene and 
natural processing of the ACBP protein. The following results were obtained. 
 
I The mouse ACBP gene was isolated and characterized. There were no observed differences in the 
coding sequence of the construct and it contained all the regulatory regions published so far. The 
continually elevated levels of ACBP resulted in enlargement of the lateral ventricles both in mice and 
rats. In addition, in mice, ACBP overexpression resulted in decreased plasticity of excitatory synapses 
and impairment of the hippocampus-dependent form of learning and memory. In contrast to previous 
results, our animals did not show any signs of anxiety or pro-conflict behaviour nor did we find any 
influence on the kainate or pentylenetetrazole induced seizure activity in the transgenic mice. 
 
II In metabolic phenotyping, our rat line overexpressing the mouse ACBP gene under the genes own 
promoter region was utilized. The transgenic rats had a significantly increased acyl-CoA pool both in 
liver and adipose tissue. Changes in the acyl-CoA pool were found to be tissue and acyl-CoA form 
specific. In addition, the ACBP induced changes were dependent on the nutritional state of the animals. 
On the contrary, there were no changes in the serum free fatty acid or plasma triglyceride and cholesterol 
levels and also the glucose tolerance of the transgenic animals remained unchanged. Although the 
physiological effects of ACBP were limited, the overexpression caused marked changes in the regulation 
of gene expression. Peroxisome proliferator activated receptors (PPARγ, PPARδ) and sterol regulatory 
element-binding protein-1 (SREBP-1) mRNA levels were significantly reduced (by 23–82%) in liver and 
adipose tissue of fed transgenic rats. In addition, adenosine monophosphate-activated protein kinase 
(AMPK) protein levels were increased (by 60%). These changes were dependent on the nutritional state 
of the animals, fasting abolished the reduction of PPARs and SREBP-1 in the liver, while evoking up-
regulation of PPARs in adipose tissue. Our results indicate that the reduction of SREBP-1 seems to be 
mediated through AMPK, whereas the regulation of PPARs is AMPK independent. These results 
demonstrate an important feedback loop; ACBP expression is regulated by both PPARs and SREBP-1. 
 
III To investigate further the role of ACBP in the physiology and regulation of gene expression, we 
challenged our ACBP overexpressing rat line with two high fat diets enriched with either medium or 
long chain fatty acids for four weeks. Transgenic animals fed with the medium chain diet had improved 
glucose tolerance and lower serum insulin levels compared to controls. In addition, their liver PPAR  (by 
43%) and SREBP-1 (by 35%) mRNA levels were reduced, while the adipose tissue PPAR  levels were 
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increased by 37%, pointing to a possible mechanism by which ACBP may improve glucose tolerance. 
The LC diet fed transgenic rats exhibited no differences in the glucose or insulin levels compared to 
controls, but they had increased levels of liver PPARs and SREBP-1 (1.5-3.5 times higher) and 
decreased protein levels of AMPK  (by 48%). This can suggest that the LC diet increased the overall 
lipid metabolism of the transgenic rats. 
 
IV It has been shown that the hypothalamic regulation of food intake is influenced by fatty acids, 
especially their intracellular active forms, acyl-CoAs. Since there was no previous data on the effects of 
fatty acid / acyl-CoA binding proteins on these processes, we examined whether constant overexpression 
of ACBP could influence the hypothalamic regulation of food intake and gene expression. Our results 
indicated that ACBP did not influence the food intake or the weight of the animals. Further 
investigations revealed that fed tg rats had significant changes in their gene expression profile: mRNA 
levels of FAS were reduced while the levels of CPT-1c were increased. Both of these proteins have been 
previously shown to play important roles in the regulation of food intake. In addition, mRNA levels of 
transcription factors and protein levels of AMPK were measured. Fed transgenic rats displayed no 
differences in the AMPK protein levels or SREBP-1 mRNA expression, but had reduced levels of 
PPAR  and SIRT-1, indicative of a possible regulatory mechanism behind the observed changes in the 
FAS and CPT-1c expression and revealing possible further regulatory targets of ACBP induced gene 
expression in hypothalamus. 
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